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 2 
Introduction 
 
My PhD study programme has been focused on pharmacoepidemiologic topics. 
Pharmacoepidemiology applies epidemiologic reasoning, methods and knowledge to the 
study of the uses and effects, beneficial and harmful, of medications in a defined population.  
Pharmacoutilization studies, in particular, aim at collecting the prescriptive profile of the 
sample investigated.  
Beside risk/effectiveness evaluations or the compliance assessment to a treatment, drug intake 
may be a indirect clue of the healthiness of the studied population since it is the marker of a 
disease severe enough to require a medication.  
Data concerning the use of prescribed medications and over the counter (OTC) may also 
allow to evaluate potential risks of drug-drug interactions (DDI) which represents a particular 
concern especially in the elderly, where polypharmacy is extremely common.  
DDI may be represented by a pharmacokinetic or pharmacodynamic interference of  drugs on 
each other, which can determine an impaired effectiveness or an increased toxicity and is one 
of the main causes of adverse drug reaction, being responsible for up to 23% of hospital 
admissions (Secoli 2010).  
In this context I have performed a pharmacoutilization study investigating the risk of potential 
DDI between treatment potentially used in dentistry and the prescribed medications/OTC 
used by outpatients attending a dental clinic. 
Moreover, pharmacoepidemiology surveys offer the possibility to investigate use and 
attitudes towards other agents such as dietary supplements (DS), herbal remedies (HR) and 
illicit substances such as doping.  
Indeed, the use of the these substances appears to be raising, thought studies in literature are 
quite scarce.  
Therefore, I decided to investigate the use, knowledge (benefits and risks) and attitudes 
towards these agents within sports.  
I have also deepened the herbal remedies topic HR performing an extensive review of the 
existing literature and followinf s muticenter study in the setting of multiple sclerosis. 
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Prescribed medication and risk of DDI in dentistry 
Drug profile in patients attending dental clinics has been poorly investigated since the few 
pharmacoutilization studies present in literature were often focused on the use of drugs by the 
dental practitioner (Gómez-Oliván 2007; Ciancio 1998) and, in some cases, on specific class 
of medications such as NSAID or antimicrobials (Epstein 2000; Cherry 2012; Levrini 2008).  
Therefore, though the most common medication prescribed in dentistry presents a large 
therapeutic index, DDI with prescribed medication, as well as with DS or HR may occur 
(Moore 1999-partI). Indeed, since they do not require prescription, DS and HR become in the 
last decades a substantial and growing part of health-care behaviour in affluent nations 
(Bailey 2012). 
The risk of DDI in dental patients is a matter of concern since the prevalence of elderly dental 
patients is growing and the need for complex procedures is raising (Hersh 2008). 
Polypharmacy and pharmacokinetics/pharmacodynamics changing due to aging make these 
subjects especially vulnerable to risk for adverse drug reactions and DDI (Corsonello 2010). 
The aim of the following study “Prescribed medication and risk of drug-drug interaction in 
dentistry: a survey in ambulatory patients” was to investigate the risk of DDI in dentistry 
patients investigating any potential interaction between drug or DS/HR used and common 
treatments in dentistry. 
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Prescribed medication and risk of drug-drug interaction in 
dentistry: a survey in ambulatory patients 
 
Abstract 
Objectives: Drugs used in dental practice have often a large therapeutic index, are usually in 
a single dose or in short-term form and frequently used for elective procedures, however, 
drug-drug interactions (DDI) with prescribed medication, as well as with dietary supplements 
(DS) or herbal remedies (HR) may occur. Nevertheless, pharmacoepidemiologic data in this 
field are scarce. The aim of the present study was to investigate the risk of DDI in dentistry 
patients investigating use pattern of drugs and DS/HR. 
Methods: Dentistry outpatients were consecutively enrolled and surveyed through a semi-
structured questionnaires divided into three sections in order to collect sociodemographical, 
pharmacological, DS and HR data. Potential risk of interactions was evaluated checking any 
potential interaction reported in literature between the drugs, DS and HR used in the studied 
population and treatments commonly used in dentistry practice. 
Results: 100 patients were enrolled, 37% were under prescribed medications, mainly 
represented by cardiovascular drugs. 82 potential DDI were detected and were principally 
represented by potential interactions with NSAIDs (88%) and antimicrobials (75%). 
Conclusions: The study underlines that dentistry outpatients are often under a 
pharmacological tretament and polypharmacy is not unfrequent, with a high risk of DDI with 
treatment prescribed by the dentist. Therefore, a careful evaluation of all the medications 
including DS and HR and a the knowledge of potential interactions with dentistry treatments 
is mandatory to avoid the risk of DDI. 
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Introduction 
Little is known about drug prescription and use in patients attending dental clinics (Carter 
2007; Brindley 2003; Miller 1992). Indeed, the few studies present in literature available are  
often focused on drug prescription by the dental practitioner (Gómez-Oliván 2007; Ciancio 
1998) and, in some cases, on patient use of specific class of medications such as NSAID or 
antimicrobials (Epstein 2000; Cherry 2012; Levrini 2008).  
The most common medication prescribed in dentistry are represented by a limited number of 
therapeutical agents: antimicrobials, analgesics, local anesthetics, sedatives and axiolytics and 
vasoconstrictors (Gómez-Oliván 2007; Ciancio 1998). Though these medication have often a 
large therapeutic index, are usually in a single dose or in short-term form (five to 10 days) and 
frequently used for elective procedures, drug-drug interactions (DDI) with prescribed 
medication, as well as with dietary supplements (DS) or herbal remedies (HR) may occur 
(Moore 1999). 
DDI can be defined as a pharmacokinetic or pharmacodyamic interference of drugs on each 
other, which may result in impaired effectiveness and/or increased toxicity. Indeed, DDI is 
one of the main causes of adverse drug reaction, being responsible for up to 23% of hospital 
admissions (Secoli 2010).  
Since drug use increases significantly with age (Moore 1999-partI) the polypharmacy is 
common among older people, representing a major concern in the care of these subjects. In 
addition aging is associated changes in pharmacokinetics such as impaired drug clearance and 
pharmacodynamics with a progressive decline in homeostatic mechanisms, make these 
subjects especially vulnerable to risk for adverse drug reactions and DDI (Corsonello 2010). 
Moreover, the prevalence of elderly dental patients is growing and due to the reduction of 
edentulism and tooth loss, the need for complex periodontal, implant and restorative 
procedures is raising (Hersh 2008). 
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Similarly to elderly patients, paediatric dental patients due to their particular physiology  and 
anatomy (increased receptor sensitivity, narrow nares, large tongue, high glottis, smaller 
diameter of the airway passages) are particularly vulnerable to drug interactions, especially 
involving multiple central nervous system agents such as local anaesthetics together with 
narcotic sedatives (Hersh 2008). 
Besides prescription medicines, another source of DDI is increasingly represented by dietary 
supplements (DS) or herbal remedies (HR). DS and HR do not require prescription and they 
became in the last decades a substantial and growing part of health-care behaviour in affluent 
nations (Bailey 2012). 
Therefore, the aim of the present study was to investigate the potential for DDI in dentistry 
patients by assessing in a cohort of outpatients attending a dental clinic: (i) the use pattern of 
prescription and non-prescription medicines as well as of DS/HR; (ii) the relationship 
between medicines and/or DS/HR use and socio-demographic features of the surveyed 
population; (iii) the potential for the occurrence of DDI between medicines and/or DS/HR 
used and common treatments in dentistry. 
 
Materials and methods  
The Department of Orthodontics is a University Clinic (University of Insubria, Varese, Italy) 
where a mean of 180 specialist visits takes place each month. Two kinds of typical patient 
may be observed: the first one is represented by under 15 who are part of prevention programs 
of odonthoiatric pathologies or require orthodontic treatments. A second group of patients is 
composed by adults with complex odonthoiatric conditions. 
Patients who attended the Department of Orthodontics for a specialist visit and giving their 
written consensus to participate to the survey were consecutively enrolled from January to 
February 2010. 
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Participants were surveyed through a semi-structured questionnaire devised to investigate: 
socio-demographical characteristics: age, sex, body mass index (BMI), education, place of 
living; pharmacological treatment: drug used, dose regimen, root of administration; use of 
DS/HR (name, composition, dose regimen, route of administration). 
All the information were gathered through a telephonic interview when the patients were at 
home and had the time to check for the proper name of drug as well as DS/HR used. 
The study was conducted in accordance with the WMA Declaration of Helsinki and written 
informed consent was obtained from all participants. 
To investigate the potential risk of interactions, the drugs as well as DS/HR used were 
examined singularly with the aim to check any potential interaction reported in literature with 
treatments commonly used in dentistry practice. 
 
Data analysis 
Collected data were inserted in a digital archive and analyzed through a descriptive approach. 
Data were expressed as mean±standard deviation (SD). Anthropometric data, height and 
weight were expressed as body mass index (BMI, kg/m2). Prescribed drugs were codified 
according to the WHO Anatomical Therapeutic Chemical (ATC) classification system 
(http://www.whocc.no/atc/structure_and_principles/). Statistical significance of the 
differences among groups was examined using the χ2-test distribution, the unpaired t-test, 
ANOVA or the Pearson correlation test, as appropriate. 
 
 8 
Results 
 
Socio-demographic features 
100 subjects (56% male) with a mean age of 33.3±25.6 years (range 2-87) were consecutively 
enrolled. In 41% of cases patients were younger than 15 years. Even if excluded the youngest 
groups (i.e., <15 years and 15 to 24 years), a primary level of education was reported in the 
majority of cases (24%). Table 1 shows the socio-demographic features of the whole sample, 
as well as divided according to age group. 
 
Drug use 
37% of the population (59% male, mean age 52.5±23.9 years) were under a pharmacological 
treatment, for a total of 103 medication, 2.8±2.0 per user (range: 1-8). In table 2 the use of 
medications among the different classes of age is described in details. Cardiovascular drugs 
were the most commonly used medications (33%) and were used by 54.1% of patients (Table 
4). If considered the singular active principle, the mainly represented was acetylsalicylic acid 
(8.7%), used as antithrombotic preparation by 24.3% of the patients. 
 
Dietary supplements/Herbal remedies 
6%, 5 female and 1 male, with a mean age of 34.5±13.7 years (range: 19-56) used on the 
whole 7 DS/HR, a mean of 1.2±0.4 DS/HR per subject (range: 1-2). The substances were 
represented by a complex of aminoacids together with vitamins B group in 5 cases (71.4%), 
and by HR in the remaining 2 (Undaria pinnatifida associated with Opundia Ficus-indica in 
one case, and Lagerstroemia, Ginseng, Blueberry, royal jelly and Eleutherococcus in the other 
case).  
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Potential drug-drug interaction 
82 potential interaction with medication commonly used in dentistry were observed in 24 
subjects (64.9% of patients under medication), with a mean of 3.4±2.5 DDI/subject (range: 1-
8) In Table 5 are presented all the potential DDI with drugs commonly used in dentistry. 
The contemporary intake of medications and DS/HR occurred in only one subjects 
(carbocisteine together with an aminoacid supplement). However, no literature data 
concerning potential risk of interaction with the medication used were found. 
 
Correlations 
Drug use presents a linear correlation with age (r2=0.29; P<0.0001). Potential DDI were 
related to the number of drugs used (r2=0.65; P<0.0001). None of the other socio-
demographic features considered appeared to be relate to the pattern of drug use. 
The intake of DS and HR were neither influenced by socio-demographic features nor by drug 
use. 
Number of medication used as well as age, significantly differed between the subjects at risk 
for DDI and who were not (3.6±2.0 vs 1.2±0.5 drug/subject, respectively, P<0.0001; 
64.3±14.1 vs 31.2±24.1 years, respectively, P<0.0001). Linear correlations were observed 
between age (r2=0.17; P<0.01) and number of drug used (r2=0.59; P<0.0001). 
 
Discussion 
 
Medication, DS and HR use 
The use of prescribed medications interested one third of the studied population and was 
comparable to available data in similar setting (26-44%) (Carter 2007; Brindely 2003; Miller 
1992). 
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As occurs also in the general population, prevalence and number of drugs used increased with 
age with a linear correlation (Rapporto OSMED 2009; Carter 2007; Miller 1992), reaching a 
prevalence of 100% in the over 64. 
Cardiovascular drugs are the most common drug group that dentists encounters, interesting 
half the patients as also observed in our sample (Becker 2007; Carter 2007).  
In particular, ASA, used as antiplatelet drug, resulted the most prescribed active principle 
(8%), in accordance with a prevalence of 8% in the general population (Rapporto OSMED 
2009). 
The prevalence of HR and DS, interesting 6% of the studied population, was similar to that 
reported in literature the Italian population (Menniti-Ippolito 2002). We are aware that DS 
and HR are often under reported by the patient during the visit, for that reason  a specific 
section of the questionnaire was devoted to the use of these substances. 
DS use appears to be spread interesting up to half of in the general population (Bailey 2012), 
however, though the intense marketing and promotion, only a few rigorous studies have been 
performed, therefore, the actual advantage of supplementation is controversial (Dascombe 
2010). A balanced diet allows to avoid the risk of vitamin or mineral deficiency, therefore, 
dietary supplementation is usually unnecessary if not dangerous since DS may cause adverse 
reactions due to contaminants or other substances (such as drugs) not declared on  the label  
(Gullotti Codaro 2011; Geyer 2008). 
Moreover, the use of HR represents a matter of concern especially in particular groups of 
individuals (such as children, elderly, pregnant women), or in patients suffering from chronic 
disease and/or undergoing to surgery, who may present physiological or pathological 
differences in herbal metabolism, a potential increased risk of adverse events or interferences 
with conventional treatments.  
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Potential drug-drug interaction 
More than 80 potential DDI have been found in two thirds of drug users. The risk for DDI 
was related to the number of medication used and the group at risk used a mean of more than 
three drugs (up to 8 drugs). Not surprisingly, due to the direct correlation to the number of 
drug used, also age presented a linear correlation with DDI risk. Polypharmacy is common in 
the elderly and is a major concern in the care of these subjects, due polymorbidity, with 
increased number of chronic diseases and changing in the pharmacokinetic and 
pharmacodynamic response (Corsonello 2010) and the higher risk of adverse drug reactions 
and DDI (Planton 2010; Antithierens 2010). 
It has been estimated that more than 30% of drugs taken by dental outpatients may produce 
dentally related side effects, such as xerstomia, abnormal bleeding, etc, but also DDI, and this 
percentage raises up to 90% in the elderly (Miller 1992). 
The exact prevalence of DDI risk in dentistry has so fare not clearly been established. The 
findings of the present study were used to discuss the potential DDI with drugs commonly 
prescribed in dentistry in the light of the available literature. 
 
Antimicrobials 
Antifungal azolics and antibiotics represented are commonly used in dental practice (Hersh 
1999). If excluded single-dose prophylactic regimens for endocarditis and articular prothesis, 
the treatment with antimicrobial agents is usually more prolonged than other types of drug, 
from 5 to 10 days (Hersh 2008; Hersh 1999). Therefore, the patient is exposed to a increased 
risk of DDI, compared to other drug classes, due to the fact that some antimicrobials are able 
to inhibit gut and liver cytochrome P450 system, enhancing, therefore, plasma levels of other 
drugs that share the same metabolic pathway and increasing the toxicity (Hersh 1999) .  
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Indeed, antibiotic (clatithromicin, erythromycin, ciprofloxacin and metronidazole) as well as 
antifungal azolics (fluconazol, ketoconazol) are potent inhibitors of several cytochrome 
P(CYP)450 isoforms. In particular  CYP1A2 is inhibited by macrolids (erythromycin, 
clarithromycin) and ciprofloxacin, CYP2C9 is inhibited by metronidazole and antifungal 
azolics (fluconazol, ketoconazol) and CYP3A4 is inhibited by macrolids (erythromycin, 
clarithromycin), metronidazole and antifungal azolics (fluconazol, ketoconazol (Hersh 2008; 
Sims 2007; Gomez-Moreno 2009; Hersh 2004). 
We found 27 potential interaction with antimicrobial treatment in 3 quarters of the drug users. 
 
Anticoagulants 
The potential severe DDI with antimicrobials are mainly represented by interactions with 
anticoagulant treatment (warfarin, acenocoumarole) (Hersh 1999), due to the relatively low 
therapeutic index of these drugs. Patients with prosthetic heart valves are considered at high 
risk for infective endocarditis and need to be treated with a single oral dose of penicillin and 
only isolated cases of increased prothrombin time and bleeding have been reported, 
suggesting the importance to monitor the patients under anticoagulant treatment (Bhatt 2000). 
Macrolids, metronidazole and fluconazole may be involved in the interaction with oral 
anticoagulants such as warfarin (metabolized by CYP2C9 and CYP3A4) and acenocoumarole 
(metabolized by CYP2C9) increasing prothrombin time and INR with risk of bleeding 
(Gomez-Moreno 2009; Horn 2010; Howard-Thompson 2008; Thijssen 2003). In addition, 
also topical use of antifungal oral gel may be a poorly recognize way of interfere similarly 
anticoagulant activity (Silingardi 2000; Ezsias 1997). 
Antibiotic treatment with tetracyclines or other broad spectrum antibiotics may alter gut flora 
and impair the absorption of vitamin K, essential cofactor in the synthesis of vitamin K-
dependent clotting factors VII, IX, X (Sims 2007). However, significant interactions may 
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occur only in patients with poor vitamin K intake (Hersh 1999). Several cases of increased 
INR and bleeding in patients under oral anticoagulants prescribed also tetracycline have been 
reported in literature (Stockley 1996; Westfall 1980; O’Donnel 1989), though one study 
observed no interactions (Hersh 1999).  
Moreover, cases of increased anticoagulant activity under amoxicillin and ampicillin and one 
report about a slight reduction of prothrombin times in five patients taking amoxicilln 
appeared in literature (Hersh 1999). These evidence suggests that the potential interactions of 
these last antibiotics is rare and unpredictable and may be of most concern in patients with 
deficient intake of vitamin K. 
Therefore, before prescribing metronidazole, tetracycline or antifungals azoli in patients on 
chronic anticoagulant treatment a consultation with the prescribing physician is advised. 
Azythromicin presents a few interactions with drugs metabolized by CYP3A4 and may be, 
therefore, a safe alternative in patients treated with drugs metabolized by CYP3A4 (Gomez-
Moreno 2009). 
Since metronidazole is usually prescribed for anaerobic component of oral infections together 
with penicillin used for the aerobic one, clindamycine has been suggested as a valid 
alternative in these cases (Gomez-Moreno 2009) 
 
Proton pump Inhibitors 
Ketoconazole absorption could be impaired by the reduction of gastric acidity consequent to 
proton pump inhibitors use (Hersh 2008; Blume 2006). Therefore, antifungals efficacy should 
be significantly impaired in the two patients of the study who were under omeprazole or 
lansoprazole. 
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Immunosuppressants 
DDI with tacrolimus used as immunosuppressant in solid organ transplant as well as in the 
treatment of autoimmune disorders (psoriasis, rheumatoid arthritis) has been described in 
literature (Gomez-Moreno 2009). Tacrolimus is a substrate of CYP3A4, therefore, the 
inhibition of this isoenzymes by macrolids may determine the substrate accumulation and 
leading, therefore, to an excessive immunodepression and nephrotoxicity (Gomez-Moreno 
2009). 
 
Estrogens and progestines  
The potential contraceptive failure under antibiotic treatment is controversial (Sims 2007; 
Hersh 1999). Estrogens and progestines as substrate of CYP3A4 (Hersh 2008; Hersh 2004), 
but, none of the commonly used antibiotic in dentistry are inhibitors of CYP3A4 and may, 
therefore, raise the level of oral contraceptive (Back 1990). Though cases of contraceptive 
failure have been reported in literature (Bainton 1986), clinical studies have not proven 
significant reduction in blood levels of these drugs neither of their efficacy (Hersh 1999). The 
anecdotic cases may be due to an impairment in the enterohepatic recycling of the conjugated 
estrogens reactivated, liberating the parent compound by gut flora and reabsorbed as active 
drug (Sims 2007; Gomez-Moreno 2009), observed in animal models (Hersh 1999; Gibson 
1994; Back 1982). Though the real effects are still debated, dentist should inform oral 
contraceptive users concerning the potential risk of this DDI. 
 
Statins 
Macrolids and azole antifungal agents should be avoided in patients under statins. Increased 
levels of statins may determine higher risk for myophaty and hepatotoxicity (Becker 2008). 
Significant cases of rabdomyolisis, due to the association of statins and antimicrobial has been 
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reported especially for simvastatin due to the fact that, together with atorvastatin, is substrate 
of CYP3A4 (Mazzu 2000). CYP metabolism of rosuvastatin appears to be minimal and is 
principally mediated by the 2C9 enzyme, with little involvement of 3A4 (Thijssen 2003). 
 
Calcium-channel blockers 
Calcium-channel blocker such as Verapamil may compete with macrolide for CYP3A4. As a 
consequence, toxicity due to elevated levels of macrolides (cardiac toxicity due to prolonged 
QT) or verapamil (bradycardias and atrioventricular block) may occurr. 
 
Drugs acting on central nervous system 
Lorazepam, fluorazepam and fluoxetine are substrates of CYP3A4, therefore, metronidazole 
and antifungal azolics, acting as inhibitors, may prolong and enhance the sedative effects of 
these agents (Grimm 2006). 
Quetiapine is mainly metabolized by CYP3A4, therefore the concomitant use of the 
aforamentioned inhibitors may considerably affect the clearance of this antipsychotic. As a 
consequence extrapyramidal effects of postural hypotension may occurr (Urichuk 2008; Prior 
2003; Grimm 2006). 
 
 
Vasoconstrictors 
 
Vasoconstrictors (i.e. epinephrine or levonordefrin) represent a considerable source for DDI 
(6 cases in 21% of drug users in our studied population) since they are widely used in 
dentistry to localize the injection of local anesthetic to the site of administration and to 
decrease local bleeding (Yagiela 1999).  
Vasoconstriction occur through the stimulation of  α 1 receptors in the peripheral vessels. In 
particular epinephrine equally stimulates α and β receptors, while levonordefrin presents a 
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higher selectivity for α receptor (three times as much as β1). As the result, epinephrine has 
less pressor effects due to opposing vasodilatatory property since the vasoconstriction 
mediated by α receptor in certain districts are counterbalanced by vasodilatation mediate by 
β2 stimulation on other vascular beds were β2 prevail such as in skeletal muscle (Hersh 
2008). 
 
β-blockers 
In our study 3 patients were concomitantly treated with β-blockers, 2 with selective β-blocker 
metoprolol and 1 with non selective β-blocker carvedilol. When epinephrine or levonordefrin 
are administrate in concomitance with non selective β-blockers severe DDI may occur with a 
dose-related pattern (Hersh 2008; Centeno 2003; Mito 1988). Grimm 2006). Vasoconstrictors 
through α-stimulation may determine a pronounced vasoconstriction up to a hypertensive 
crisis or a cerebrovascular accident. β2 vasodilatatory and β1 cardiostimulatory effects of 
epinephrine are inhibited by non selective β-blockade  (Hersh 2008). In contrast, a lack of 
significant blood pressure increase has been observed with selective β-blocker and 
epinephrine but not with levonerdefrin since this last agent does not stimulate β2 receptors 
responsible of peripheral vasodilatation (Hersh 2008; Gomez-Moreno 2009; Hjemdahl 1983; 
Rehling 1986). However both selective and non selective β-blockers impair the clearance of 
epinephrine and norepinephrine. Therefore, an initial test dose carefully injected in order to 
avoid intravascular administration followed by a careful monitoring of  blood pressure is 
recommended in patients under this treatment. And if the hemostasis is not required and the 
procedure is relatively short, vasoconstrictors should be avoided (Hersh 2008). 
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Thyroid hormones 
Inappropriate use of preparation of thyroid hormones may determine cardiovascular changes 
(Gomez-Moreno 2009) as a results of  a chronic overstimulation of myocardial metabolism 
(Klein 1990). Therefore, adrenergic vasoconstrictors should be carefully used in patients with 
increased thyroid stimulation (Gomez-Moreno 2009; Yagiela 1999). 
 
Antipsychotic agents 
Another potential receptorial interference with vasoconstrictors is the use of antipsychotic 
such as quetiapine (in 1 patient) that is able to block α-receptors therefore, when patient is 
administered vasoconstrictors, β agonism effects prevail, determining increased heart rate 
and, in case of epinephrine, also peripheral vasodilatation with, as a consequence, orthostatic 
hypotension and reflex tachycardia (Sims 2007; Yagiela 1999). In addition, due to their 
antagonism to α-receptors, antipsychotic may considerably impair the effectiveness of 
vasoconstrictor (Sims 2007). 
 
 
NSAIDs 
 
NSAIDs are commonly prescribed in dentistry for postoperative pain and in our sample were 
related to 34 potential DDI, potentially interesting 88% of the patients under prescribed 
medications. 
 
Antihipertensive agents 
The treatment with NSAIDs for more than 5 days may impair the efficacy of antihypertensive 
drugs such as diuretics (especially loop diuretics), β-blockers and ACE inhibitors and 
angiotensin-receptor blockers, due to the inhibition on the production of vasodilatatory 
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prostaglandins responsible for the increase of renal blood flow (Hersh 2008; Becker 2007; 
Gibson 2007; Huston 1991). 
 
Anticoagulant/antiplatelet treatment 
NSAIDs prescription in patients using warfarin increases the risk for gastrointestinal bleeding 
fourfold to five fold (Becker 2008; Delaney 2007). With the exception of acetil salycilic acid, 
most NSAIDs presents minimal antiplatelet effects (Sims 2007; Becker 2008), but the actual 
concern is the risk of gastroduodenal erosion and bleeding in patients under NSAID, 
especially if associated with other antiplatelet treatments (i.e. ticlopidine) (Cadiou 2012). 
In addition, it has been debated whether NSAIDs such as ibuprofen may impair antiplatelet 
effects competing with acetil salycilic acid for COX inhibition. Indeed, ibuprofen presents 
antiplatelet effect, though temporary, due to a reversible inhibition of COX (Catella-Lawson 
2001). However,  according to a randomized study, the antiplatelet activity of acetil salicylic 
acid was preserved during concomitant ibuprofen administration (Cryer 2005). 
 
Metotrexate 
In patients under metotrexate, NSAIDs should be used carefully, due to the relatively low 
therapeutic index if this drug and the potential severe side effects such as thrombocytopenia, 
neutropenia, renal failure. Indeed, NSAID may cause an impaired renal perfusion, thus 
increasing the risk for potential side effect due to a reduced metotrexate clearance (Hersh 
2008; Frenia 1992). 
 
Selective Serotonine Reuptake Inhibitors (SSRIs) 
SSRIs, such as fluoxetine and escitalopram, decrease platlet aggregation due to the inhibition 
of the reuptake of serotonin and the downregulation of serotonin receptors also at platelet’s 
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level and, therefore, enhance the risk of bleeding (Serebruany 2006; Hersh 2008). Therefore, 
the concomitant use of NSAIDs in patients under SSRI should be avoided. Indeed, the risk of 
gastrointestinal bleeding following NSAIDs treatment raises from 3.7-4.5 up to 15.6-16.7 in 
patients concomitantly under SSRI, an effect which is greater than a simple additive effect of 
each individual class (Dalton 2003; De Abajo 1999; Langman 1994). 
 
Narcotic analgesics 
Patients treated with opioid analgesics during conscious sedations or to manage post-
procedural pain  are at risk of serious DDI (Hersh 2008; Haas 1999).  
In a quarter of the patients under medications, 6 potential DDI with narcotic analgesics and 
drugs acting on central nervous system tramadol, antipsychotics (quietapine), benzodiaepines 
and SSRI were detected.  
Due to their depressant effects on the central nervous system the prescription of narcotic 
analgesic in presence of another central nervous system depressant such as other central 
analgesics and benzodiazepines can determine additive or supra-additive depression, 
excessive psychomotor impairment, sedation and uncosciousness (Hersh 2008; Sims 2007; 
Haas 1999).  
Moreover, since opioid analgesics determine peripheral vasodilation, the may enhance 
orthostatic hypotension and, therefore, increase postural instability and the risk of falls in 
patients treated with antipsychotics with α blocking properties such as quetiapine (Sims 
2007). 
In patients concomitantly treated with SSRI, opiods such as tramadol and meperidine may 
precipitate and acute serotonin syndrome characterized by confusion, agitation, hyperthermia, 
diaphoresis, sinus tachycardia, tachypnea, hypertension (Sims 2007; Becker 2008). 
 
 20 
Sedative and anxiolitics drugs 
Benzodiazepine are used in dentistry practice in order to provide anxiolysis, sedation and 
skeletal muscle relaxation. 9 potential DDI have been found out in one third of drug users. 
 
CNS depressants 
The association of two or more CNS depressant (such as quetiapine, or other 
benzodiazepines) may increase the levels of central depression with excessive sedation and 
respiratory depression (Sims 2007). 
  
Fluoxetine and verapamil 
Fluoxetine and Calcium-channel blocker verapamil, due to inhibition of CYP3A4, may 
prolong the duration of sedation, inhibiting metabolism of benzodiazepines (Hersh 2008; 
Becker 2007; Sims 2007; Moore 1999). These combination should be avoided especially in 
the elderly, who are particularly sensitive to benzodiazepine sedation (Hersh 2008). 
 
Oral anticoagulants 
The oral sedative chloral hydrate, due to a displacement interaction (competition for plasma 
protein binding) with oral anticoagulant may cause hypothrombinemia. This effect is transient 
and may be clinical insignificant especially with single dose of chloral hydrate (Moore 1999).  
 
Conclusions 
The present study underlines that very often patients attending a dental clinic may be under a 
pharmacological treatment and polypharmacy is not unfrequent. As the population becomes 
older there is a subsequent raise in drug prescription and therefore in the risk of DDI. 
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Indeed, the importance of patients' medical histories will increase along with the number of 
medically complex patients who visit the dental general practice 
Preoperative assessment of dental patients including a complete evaluation, documenting all 
the medications including within the dental record also DS and HR, enables the dentist to 
design a treatment plan that avoid potential DDIs. Dentists should also be informed about HR 
and DS that may affect efficacy and safety of dental treatment, since many consumers do not 
report their health care providers about them. Moreover, dentists should be aware of how 
patient’s prescribed medications may interact upon dental treatment.  
Therefore, medication profiles and potential DDI knowledge is essential for safe practice in 
dentistry and also represents an important base for planning undergraduate as well as 
postgraduate teaching in clinical pharmacology. 
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Tables 
Table 1. Socio-demographic features of the sample population divided according to age. 
Age (years) <15 15-24 25-34 35-44 45-54 55-64 >64 Tot 
Sex          
Male 28 1 5 2 4 3 13 56 
Female 13 6 3 6 4 9 3 44 
Total 41 7 8 8 8 12 16 100 
        
 
BMI (kg/m2)          
(mean±SD) 19.3±2.1 20.6±2.8 23±2.4 22.6±2.4 24.7±4.7 22.9±1.9 24.6±1.6 21.6±3.3 
        
 
Marital status         
Single 41 7 7 3 0 1 1 60 
Married/cohabiting 0 0 1 4 8 8 12 33 
Separated/divorced 0 0 0 1 0 0 1 2 
Widowed  0 0 0 0 0 3 2 5 
        
 
Place of living         
<5’000 inhabitants 12 4 1 3 2 5 3 30 
~10'000 
inhabitants 11 0 3 1 4 1 3 23 
~20'000 
inhabitants 5 1 0 0 1 3 3 13 
>20'000 
inhabitants 13 2 4 4 1 3 7 34 
 
       
 
Education         
Primary school 11 0 2 3 4 4 11 35 
Lower Secondary 4 4 1 1 2 6 3 21 
Upper secondary 
school 0 3 2 3 2 2 2 14 
Bachelor  0 0 3 1 0 0 0 4 
None 26 0 0 0 0 0 0 26 
        
 
Occupation         
Student 33 6 2 0 0 0 0 41 
Retired 0 0 0 0 0 7 16 23 
Blue collar 0 1 0 1 3 1 0 6 
White collar 0 0 3 5 2 0 0 10 
Unemployed  0 0 0 1 1 1 0 3 
Self-employed  0 0 0 0 0 2 0 2 
Housewife  0 0 1 1 0 1 0 3 
NONE 8 0 2 0 2 0 0 12 
 
 23 
Table 2. Drug use divided according to age and sex. 
Age (years) <15 15-24 25-34 35-44 45-54 55-64 >64 Tot 
         
Drug Users (DU)         
Male 
        
N 6 0 0 1 2 1 13 23 
% of Total DU 16,2 0,0 0,0 2,7 5,4 2,7 35,1 62,2 
% of patients 14,6 0,0 0,0 12,5 25,0 8,3 81,3 23,0 
Female 
        
N 0 1 1 2 3 4 3 14 
% of Total DU 0,0 2,7 2,7 5,4 8,1 10,8 8,1 37,8 
% of patients 0,0 14,3 12,5 25,0 37,5 33,3 18,8 14,0 
Tot of DU  
        
N 6 1 1 3 5 5 16 37 
% of Total DU 16,2 2,7 2,7 8,1 13,5 13,5 43,2 100 
% of patients 14,6 14,3 12,5 37,5 62,5 41,7 100 37 
N of Total subjects 41 7 8 8 8 12 16 100 
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Table 3. Potential drug-drug interaction with treatment commonly used in dentistry divided 
according to age and sex. 
Age (years) <15 15-24 25-34 35-44 45-54 55-64 >64 Tot 
DDI         
Male         
N 0 0 0 0 8 0 41 49 
% of total DDI 0 0 0 0 9,8 0 50,0 59,8 
Female         
N 0 1 0 2 15 6 9 33 
% of total DDI 0 1,2 0 2,4 18,3 7,3 11,0 40,2 
Total DDI         
N  0 1 0 2 23 6 50 82 
% of total DDI 0 1,2 0 2,4 28,0 7,3 61,0 100 
        
 
DDI/DU 0 1 0 0.7±1.2 4.6±3.1 1.2±1.3 3.1±2.7 3.4±2.5 
        
 
DU with DDI 
        
Male         
N 0 0 0 0 2 0 13 15 
% 0 0 0 0 5,4 0 35,1 40,5 
Female 
        
N 0 1 0 1 2 3 3 10 
% 0 2,7 0 2,7 5,4 8,1 8,1 27,0 
Total          
N  0 1 0 1 4 3 15 24 
%  0 2,7 0 2,7 10,8 8,1 40,5 64,9 
         
Total subjects 41 7 8 8 8 12 16 100 
*data are expressed as mean ±standard deviation. DU= Drug Users; DDI= Drug-Drug 
Interaction 
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Table 4. Drug used divided according ATC classification (Part I) 
 
 Drugs  Users  
 N % N % 
     
A - ALIMENTARY TRACT AND METABOLISM 14 13,6 10 27,0 
A02 -  DRUGS FOR ACID RELATED DISORDERS 6 5,8 6 16,2 
A02BC01 – omeprazole 4 3,9 4 10,8 
A02BC03 – lansoprazole 2 1,9 2 5,4 
A10 - DRUGS USED IN DIABETES 7 6,8 4 10,8 
A10AB04 – insulin lispro 1 1,0 1 2,7 
A10BA02 – metformin 4 3,9 4 10,8 
A10BB09 – glicazide 1 1,0 1 2,7 
A10BF01 – acarbose 1 1,0 1 2,7 
A12 - MINERAL SUPPLEMENTS 1 1,0 1 2,7 
A12BA01 - potassium chloride  1 1,0 1 2,7 
     
B – BLOOD AND BLOOD FORMING ORGANS 16 15,5 15 40,5 
B01 - ANTITHROMBOTIC AGENTS 15 14,6 14 37,8 
B01AA03 – warfarin 3 2,9 3 8,1 
B01AA07 – acenocoumarol 1 1,0 1 2,7 
B01AC05 – ticlopidine 2 1,9 2 5,4 
B01AC06 - acetylsalicylic acid 9 8,7 9 24,3 
B03 – ANTIANEMIC PREPARATIONS 1 1,0 1 2,7 
B03BB01 - folic acid 1 1,0 1 2,7 
     
C - CARDIOVASCULAR SYSTEM 34 33,0 20 54,1 
C01 - CARDIAC THERAPY 1 1,0 1 2,7 
C01DA14 - isosorbide mononitrate  1 1,0 1 2,7 
C03 – DIURETICS 3 2,9 3 8,1 
C03EA01 - hydrochlorothiazide and potassium-sparing agents 3 2,9 3 8,1 
C07 - BETA BLOCKING AGENTS 3 2,9 3 8,1 
C07AB02 – metoprolol 1 1,0 1 2,7 
C07AG05 – carvedilol 2 1,9 2 5,4 
C08 - CALCIUM CHANNEL BLOCKERS 4 3,9 4 10,8 
C08CA01 – amlodipine 1 1,0 1 2,7 
C08CA02 – felodipine 1 1,0 1 2,7 
C08CA11 – manidipine 1 1,0 1 2,7 
C08DA01 – verapamil 1 1,0 1 2,7 
C09 – AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 10 9,7 10 27,0 
C09AA02 – enalapril 1 1,0 1 2,7 
C09AA04 – perindorpil 2 1,9 2 5,4 
C09AA15 – zofenopril 1 1,0 1 2,7 
C09BA07 - benazepril + diuretics 4 3,9 4 10,8 
C09CA07 – telmisartan 1 1,0 1 2,7 
C09DA04 - irbesartan + diuretics 1 1,0 1 2,7 
C10 - LIPID MODIFYING AGENTS 13 12,6 11 29,7 
C10AA01 – simvastatin 3 2,9 3 8,1 
C10AA05 – atorvastatin 6 5,8 6 16,2 
C10AA07 – rosuvastatin 1 1,0 1 2,7 
C10AX06 – omega-3-triglycerides  2 1,9 2 5,4 
C10BA02 - ezetimibe + simvastatin 1 1,0 1 2,7 
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Table 4. Drug used divided according ATC classification (Part II) 
 
 Drugs  Users  
 N % N % 
G – GENITO URINARY SYSTEM /SEX HORMONES 3 2,9 3 8,1 
G03 - SEX HORMONES/MODULATORS OF THE GENITAL SYSTEM 1 1,0 1 2,7 
G03AB06 - gestodene + estrogen 1 1,0 1 2,7 
G04 – UROLOGICALS 2 1,9 2 5,4 
G04CB02 – dutasteride 2 1,9 2 5,4 
         
H - SYSTEMIC HORMONAL PREPARATIONS* 3 2,9 3 8,1 
H02 – CORTICOSTEROIDS FOR SYSTEMIC USE 1 1,0 1 2,7 
H02AB04 - methylprednisolone  1 1,0 1 2,7 
H03 – THYROID THERAPY 2 1,9 2 5,4 
H03AA01 – levothyroxine 2 1,9 2 5,4 
     
J – ANTIINFECTIVES FOR SYSTEMIC USE 3 2,9 3 8,1 
J01 – ANTIINFECTIVES FOR SYSTEMIC USE 3 2,9 3 8,1 
J01CA04 – amoxicillin 1 1,0 1 2,7 
J01CR02 - amoxicillin + enzyme inhibitor  1 1,0 1 2,7 
J01MA17 – prulifloxacin  1 1,0 1 2,7 
     
L - ANTINEOPLASTIC/IMMUNOMODULATING AGENTS 2 1,9 2 5,4 
L01 – ANTINEOPLASTIC AGENTS 1 1,0 1 2,7 
L01BA01 – metotrexate 1 1,0 1 2,7 
L04 – IMMUNOSUPPRESSANTS 1 1,0 1 2,7 
L04AD02 – tacrolimus 1 1,0 1 2,7 
     
M - MUSCULO-SKELETAL SYSTEM 3 2,9 2 5,4 
M01 - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS  3 2,9 2 5,4 
M01AE01 – ibuprofen 1 1,0 1 2,7 
M01AH01 – celecoxib 1 1,0 1 2,7 
M01AX17 – nimesulide 1 1,0 1 2,7 
     
N – NERVOUS SYSTEM 9 8,7 9 24,3 
N02 – ANALGESICS 1 1,0 1 2,7 
N02AX52 - tramadol, combinations 1 1,0 1 2,7 
N03 – ANTIEPILEPTICS 3 2,9 3 8,1 
N03AX14 – levetiracetam 2 1,9 2 5,4 
N03AX16 – pregabalin 1 1,0 1 2,7 
N05 – PSYCHOLEPTICS 3 2,9 3 8,1 
N05AH04 – quetiapine 1 1,0 1 2,7 
N05BA06 – lorazepam 1 1,0 1 2,7 
N05CD01 – fluorazepam 1 1,0 1 2,7 
N06 – PSYCHOANALEPTICS 2 1,9 2 5,4 
N06AB03 – fluoxetine 1 1,0 1 2,7 
N06AB10 – escitalopram 1 1,0 1 2,7 
     
 
*excluding sex hormones and insulins. 
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Table 4. Drug used divided according ATC classification (Part III) 
 
R - RESPIRATORY SYSTEM 15 14,6 12 32,4 
R01 - NASAL PREPARATIONS 4 3,9 4 10,8 
R01AC02 – levocabastine 1 1,0 1 2,7 
R01AD12 – fluticasone furoate 2 1,9 2 5,4 
R01BA52 - pseudoephedrine, combinations  1 1,0 1 2,7 
R03 – DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 5 4,9 5 13,5 
R03AC02 – salbtamol 1 1,0 1 2,7 
R03AK06 - salmeterol/fluticasone 1 1,0 1 2,7 
R03AK07 – budesonide/formoterol 1 1,0 1 2,7 
R03BA05 – fluticasone 1 1,0 1 2,7 
R03BB04 - tiotropium bromide  1 1,0 1 2,7 
R05 - COUGH AND COLD PREPARATIONS 1 1,0 1 2,7 
R05CB03 – carbocisteine 1 1,0 1 2,7 
R06 - ANTIHISTAMINES FOR SYSTEMIC USE 5 4,9 5 13,5 
R06AX17 – ketotifen 1 1,0 1 2,7 
R06AX22 – ebastine 1 1,0 1 2,7 
R06AX27 – desloratadine 3 2,9 3 8,1 
     
V – VARIOUS 1 1,0 1 2,7 
V03 – ALL OTHER THERAPEUTIC PRODUCTS 1 1,0 1 1,0 
V03AE02 – sevelamer 1 1,0 1 1,0 
     
Total 103 100   
 28 
Table 5. Potential DDIs with patients’ medications (Part I) 
 
Study patients' medications that may interfere with common 
dentistry drugs 
N of 
DDI 
% of 
DDI 
N° of 
DU* 
% of 
DU* 
Antimicrobials     
A02BC01 – omeprazole 4 4,9 4 16,7 
A02BC03 – lansoprazole 2 2,4 2 8,3 
B01AA03 – warfarin 3 3,7 3 12,5 
B01AA07 – acenocoumarol 1 1,2 1 4,2 
C08DA01 – verapamil 1 1,2 1 4,2 
C10AA01 – simvastatin 3 3,7 3 12,5 
C10AA05 – atorvastatin 6 7,3 6 25,0 
C10BA02 - ezetimibe + simvastatin 1 1,2 1 4,2 
G03AB06 - gestodene + estrogen 1 1,2 1 4,2 
L04AD02 – tacrolimus 1 1,2 1 4,2 
N05AH04 – quetiapine 1 1,2 1 4,2 
N05BA06 – lorazepam 1 1,2 1 4,2 
N05CD01 – fluorazepam 1 1,2 1 4,2 
N06AB03 – fluoxetine 1 1,2 1 4,2 
  Subtotal 27 32,9 18 75,0 
  
 
 
 
Vasoconstrictors      
C07AB02 – metoprolol 1 1,2 1 4,2 
C07AG05 – carvedilol 2 2,4 2 8,3 
H03AA01 – levothyroxine 2 2,4 2 8,3 
N05AH04 – quetiapine 1 1,2 1 4,2 
 Subtotal 6 7,3 5 20,8 
  
 
 
 
NSAIDs      
B01AA03 – warfarin 3 3,7 3 12,5 
B01AA07 – acenocoumarol 1 1,2 1 4,2 
B01AC05 – ticlopidine 2 2,4 2 8,3 
B01AC06 - acetylsalicylic acid 9 11,0 9 37,5 
C03EA01 - hydrochlorothiazide and K+-sparing agents 3 3,7 3 12,5 
C07AB02 – metoprolol 1 1,2 1 4,2 
C07AG05 – carvedilol 2 2,4 2 8,3 
C09AA02 – enalapril 1 1,2 1 4,2 
C09AA04 – perindorpil 2 2,4 2 8,3 
C09AA15 – zofenopril 1 1,2 1 4,2 
C09BA07 - benazepril + diuretics 4 4,9 4 16,7 
C09CA07 – telmisartan 1 1,2 1 4,2 
C09DA04 - irbesartan + diuretics 1 1,2 1 4,2 
L01BA01 – metotrexate 1 1,2 1 4,2 
N06AB03 – fluoxetine 1 1,2 1 4,2 
N06AB10 – escitalopram 1 1,2 1 4,2 
 Subtotal 34 41,5 21 87,5 
 
  
 
 
*DU=Drug Users 
Note: subtotals of DU, may not correspond to the actual sum due to the fact that the same 
subject may use more than one drug.
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Table 5. Potential DDIs with patients’ medications (Part II) 
 
Study patients' medications that may interfere with common 
dentistry drugs 
N of 
DDI 
% of 
DDI 
N° of 
DU* 
% of 
DU* 
     
Narcotic analgesics     
N02AX52 – tramadol, combinations 1 1,2 1 4,2 
N05AH04 – quetiapine 1 1,2 1 4,2 
N05BA06 – lorazepam 1 1,2 1 4,2 
N05CD01 – fluorazepam 1 1,2 1 4,2 
N06AB03 – fluoxetine 1 1,2 1 4,2 
N06AB10 – escitalopram 1 1,2 1 4,2 
 Subtotal 6 7,3 6 25,0 
 
  
 
 
Sedative and anxiolitics     
B01AA03 – warfarin 3 3,7 3 12,5 
B01AA07 – acenocoumarol 1 1,2 1 4,2 
C08DA01 – verapamil 1 1,2 1 4,2 
N05AH04 – quetiapine 1 1,2 1 4,2 
N05BA06 – lorazepam 1 1,2 1 4,2 
N05CD01 – fluorazepam 1 1,2 1 4,2 
N06AB03 – fluoxetine 1 1,2 1 4,2 
 Subtotal 9 11,0 8 33,3 
     
Total 82 100 / / 
*DU=Drug Users 
Note: subtotals of DU, may not correspond to the actual sum due to the fact that the same 
subject may use more than one drug. 
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Drugs, dietary supplements, doping in sport 
The legal use of medication by athletes appears to be common, though poorly investigated 
(Tscholl et al., 2008; Huang et al., 2006). Indeed, although young and generally healthy, 
athletes often use a wide variety of medication to treat illness, cure injuries and obtain a 
competitive edge. Besides an indirect marker of health, as aforementioned, drug use may also 
represent in some cases a clue of doping, such as, for instance, the use of antibiotic cream in 
order to counteract acne in androgenic steroids users (Walker & Adams, 2009).  
DS consumption is common in sport, however, though the beneficial claimed in advertising, 
there is little evidence to support these contentions, since the actual advantage of 
supplementation on sporting performance is still controversial (Dascombe et al., 2010; Bishop 
et al., 2010; Maughan et al., 2007). DS are usually unnecessary if not dangerous, due to 
inadequate product labelling, presence of contaminants or undeclared substances (such as 
anabolic androgenic steroids) that may determine involuntary doping (Geyer 2008; de Hon 
2007; Van Thuyne 2006; Sundgot-Borgen 2003; Pipe 2002). 
In addition, besides contrasting evidence for benefits, DS use may, in itself, represent the first 
step to illegal preparations since it may be associated with risky behaviours such as 
inappropriate use of medication, excessive intake of energy drinks, or illicit performance-
enhancing drugs such as anabolic steroids (AS) and other doping agents (Wiefferink et al., 
2008; Papadopoulos et al., 2006).  
In “Dietary supplements and doping in cycling: use, knowledge and attitude in Italian young 
elite athletes” I have performed a survey within élite sport, i.e. young cyclists, with the aim to 
investigate doping knowledge (substances, benefits and risks and diffusion) and any factors 
potentially associated (socio-demographic characteristics, time devoted to physical activity, 
use of drugs or DS). Indeed, though suspected, the use of doping within these subjects 
remains a quite unexplored issue.  
I have also explored the setting of recreational athletes in the survey “Dietary supplements 
and anabolic substances in recreational sports: surveys in fitness centres in Northern Italy” 
aimed at collecting data concerning use and knowledge of DS and AS among recreational 
athletes. Indeed, even recreational athletes may often try to push the limits of their 
performance using performance- enhancing substances, such as DS (Guyda 2005). Moreover, 
the prevalence of AS in fitness sports appears alarmingly high, ranging from 5 to 14%, and 
represents, thus, an issue of extreme relevance for the health care system (Leifman 2011). 
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Dietary supplements and doping in professional athletes: a study 
in elite cyclists 
 
Abstract  
Dietary supplements (DS) and doping use in elite cyclists is a relatively unexplored research 
field. The aim of this study was to survey the attitude towards drugs and DS and to explore 
the knowledge concerning doping in cycling. For this purpose, an anonymous semi-structured 
questionnaire was administrated. 40 cyclists  aged 19-23 and practicing this sport for 14-30 
hour/week were interviewed. The use of drugs or DS in the last 3 months occurred in 82,5% 
and 97,5% of the participants respectively. 97,5% of the subjects were able to name at least 1 
doping agent (range 1-10); EPO the mainly represented, was mentioned by 32 athletes (80%). 
Within a fixed list of 18 substances (among which 14  were doping agents), the participants 
recognized 3-18 of them as doping. Doping knowledge appeared to be related to a higher drug 
use (r2=0.1614; p=0.01).. The main sources for doping information were internet (82,5%) and 
media in general (60%). Opinions about doping prevalence significantly differed among the 
subjects if considered cycling in general and non professional cyclers instead their own team 
(100%, 97,5% or 17,5%, respectively; p<0,001).These findings reveal the need for 
educational interventions to improve knowledge and awareness of potential dangers related to 
doping. 
 
 
Introduction 
Doping use appears to be a common practice among professional cyclists and it had been 
described as endemic (Lentillon-Kaestner & Carstairs, 2010; Schneider, 2006, Kimmage, 
2001). Besides the intent of improving physical performance, the use of banned substances 
was reported to create team cohesion and identity (Lê-Germain & Leca, 2005). However, 
doping practice appeared to be changed, switching from a team practice to a more 
individualized one (Lentillon-Kaestner & Carstairs, 2010). The use of banned substances 
seems to be influenced both by personal attitude as well as by the social environment (doctors, 
coaches, teammates, friends, etc.) (Lentillon-Kaestner & Carstairs, 2010). Thus, doping can 
be considered not just as a sport issue but as a social phenomenon. Indeed, young cyclists, 
exposed to a high pressure wishing to become professional, often seek the advice of more 
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experienced athletes, who had probably used illicit substances during their careers (Lentillon-
Kaestner & Carstairs, 2010). However, though suspected, the use of doping within the young 
cyclists remains a quite unexplored issue. 
Dietary supplements (DS) consumption is common in sport with a prevalence among elite 
athletes ranging from 57% to as high as 94%, according to different authors (Lazic et al., 
2011 Petróczi & Naughton, 2008; Huang et al., 2006; Baylis et al., 2001). The pattern of DS 
use appears to be largely sport-dependent. In particular, sports involving continuous, 
endurance-type activity, such as cycling, athletics and rowing, present the highest 
consumption of DS (Huang et al., 2006; Somerville & Lewis, 2005). Though the beneficial 
claimed in advertising, there is to date little evidence to support these contentions, since the 
advantage of supplementation on sporting performance is still controversial (Dascombe et al., 
2010; Bishop et al., 2010; Maughan et al., 2007). Among athletes with a balanced diet, the 
risk of vitamin or mineral deficiency is rare, therefore, dietary supplementation is usually 
unnecessary (Sundgot-Borgen et al., 2003). Moreover, DS presents a close relationship with 
doping, since the use may be associated to the risk of a positive doping result due to the 
presence of prohibited substances not declared on the label (Geyer et al., 2008; de Hon & 
Coumans, 2007; Van Thuyne et al., 2006; Pipe & Ayotte, 2002). In addition, DS intake has 
been found to increase the likelihood of subsequent use of doping substances and may be, 
therefore, considered as a risk factor for doping (Suzic Lazic et al., 2011; Dascombe et al., 
2010; Wiefferink et al., 2007; Papadopoulos et al., 2006). 
Although young and generally healthy, athletes often use a wide variety of medication to treat 
illness, cure injuries and obtain a competitive edge. Drug consumption may also represent an 
indirect marker of disease serious enough to require medical treatment, as well as in some 
cases a clue of doping if considering, for instance, those used to counteract typical doping 
adverse reactions, i.e. antibiotic cream for acne in androgenic steroids users (Walker & 
Adams, 2009). Nevertheless, the legal use of medication by young athletes has so far received 
little attention, even if some studies reported  prevalence around 44-61% (Tscholl et al., 2008; 
Huang et al., 2006).  
Effective doping prevention strategies need to consider doping awareness and attitudes as 
well as the frequency and patterns of use of medications and DS. The aim of the present 
investigation was therefore to gain insight into use and attitudes towards doping, drugs and 
DS among Italian young elite cyclists. For this purpose, DS as well as drug use were surveyed 
within the sample. Doping knowledge (substances, benefits and risks and diffusion) and any 
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factors potentially associated (socio-demographic characteristics, time devoted to physical 
activity, use of drugs or DS) were investigated. 
 
Methods 
Participants 
The investigation was conducted from July to August 2009, during race periods, among non 
professional élite-under 23 cyclists. Five teams were involved, all from Northern Italy: 2 from 
Lombardy, 2 from Piedmont and 1 from Veneto. Informed consent was obtained from all 
participants and the survey was conducted in accordance with ethical research guidelines. 
 
Questionnaire 
A semi-structured, anonymous questionnaire with multiple choice close and open answers 
was designed to gather the following data: 
- socio-demographical characteristics: age, education, place of living; 
- anthropometrical (height, weight); 
- information concerning cycling: time devoted, since how many years it had been played and 
if it was a full time activity; 
- information about the use of drugs within the last three months: reason for using and sources 
for information/prescribing; 
- information about the use of DS within the last three months: reason, frequency of use, 
expected and obtained benefits, and sources for information; 
- knowledge of doping agents: ability to name doping agents and to recognize them among a 
fixed list of substances, opinion concerning use and diffusion in cycling in general, among 
elite-under 23 team and in their own team, reasons for using doping, risks related and sources 
for information.  
 
Data analysis 
Collected data were inserted in a digital archive and analyzed through a descriptive approach. 
Data were expressed as mean±standard deviation (SD). Anthropometric data, height and 
weight were expressed as body mass index (BMI, kg/m2). Prescribed drugs were codified 
according to the WHO Anatomical Therapeutic Chemical (ATC) classification system 
(http://www.whocc.no/atc/structure_and_principles/). Statistical significance of the results 
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was examined using the χ2-test distribution, the unpaired t-test, ANOVA or the Pearson 
correlation test, as appropriate 
 
Results 
Participants 
Forty elite-under-23 cyclers all male were interviewed. Anthropometric and socio-
demographic features in the sample considered are presented in Table 1. 
 
Prescription drugs 
30 subjects (75,0%) have used, in the last 3 months, 84 drugs, 2,8±1,0 drugs/person (range: 1-
5). In addition, 6 DS and 1 omeopathic product (damiana compositum) were included by 
mistake by 4 subjects among prescribed drug. The most common ATC group prescribed was 
group B “Blood and blood forming organs”: 31 prescriptions (36,9%) in 22 subjects (73,3%). 
The complete list of drugs grouped according to ATC is shown in table 2. Among the 
heterogeneuos group of active principles, the most common were V03AB32 glutathione (15, 
17,9% of all prescriptions, used by 50,0% of subjects), followed by the antianemic 
preparation BA03BA cyanocobalamin (10, 11,9% of all prescriptions, used by 33,3% of 
subjects). The most common class of drugs was NSAIDs (M01A and N02B), with 14 
prescriptions (16.7%) reported by 10 subjects (33.3%). 
When provided (96,4% of subjects), reasons for using drugs were “vitamin deficiency” (27, 
32.1%), “energy recovery” (18 cases, 21.4%) , “detox” (12, 14,3%), “fever/influence” (7, 
8.3%), “unease” (5, 6.0%), “anaemia” (5, 6.0%), “pain” (4, 4.8%), “to maintain hematocrit” 
(4, 4.8%), “allergy” (2, 2,4%), “fitness maintainence” (1, 1.2%). 
 
Dietary supplements 
39 participants (97,5%) declared to have used DS in the previous 3 months. A total of 108, 
2,8±1,3 DS/person (range: 1-5), were used cyclically (47, 43,5%), daily (37, 34,3%), on 
demand (17, 15,7%), during race (5, 4,6%) and the most frequently used were aminoacids. In 
table 3 the complete list of DS use are presented. In addition, an omeopathic product 
(damiana compositum) was also listed among DS. 
When reported (92,6%), reasons for DS use were “to integrate a dietary deficiency” (53, 
49,1%), a “better recovery” (38, 35,2%), “wellness” (5, 4,6%) and “better reactions” (4, 
3,7%) 
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Benefits were observed among 27 users (69.2%) and were represented by “a better recovery” 
(16, 59,3%), “wellness” (6, 22,2%), “more strength” (4, 14,8%) and cramp prevention (1, 
3,7%).   
 
Doping 
38 (95,0%) subjects were able to name at least 1 agent considered as doping, for a total of 118 
(3,2±2 doping agent/individual; range: 1-10) and the most commonly mentioned one was 
erythropoietin (32, 27,1% %) (Table 4). In three cases were listed also non doping agents, i.e, 
tramadol in 2 (1,7%) cases and sildenafil in 1 (0,8%). 
Subjects were also asked to identify the known substances within a fixed list and to 
discriminate if they were doping or not (Table 5). The list included 18 agents, among which 
14 of them were doping according the 2009 WADA list. The surveyed subjects correctly 
identified a mean of 10,6±3,7 substances (range: 3-18), among which 7,6±2,7 (range: 3-14) 
were properly identified as doping agents. Among the most frequently recognized (by 39 out 
40 subjects), growth hormone and testosterone, were considered doping agents in 100% of the 
cases, while amphetamine in 94,8%, and within non doping agents, tramadol in 6 out of 25 
cases (24.0%). Phenmetrazine was the less recognized substances, since it was known by only 
2 (5,0%) participants and was considered as doping in both cases. On the other side, 
probenecid and albumin, known by 5 (12,5) and 17 (42,5%) subjects respectively, were 
recognized as doping agent only in 40,0% and 52.9% of cases.  
According to the majority of the surveyed (38, 95%), doping agents were globally dangerous 
with potentially serious consequences, while for 2 of them only erythropoietin, Continuous 
Erythropoietin Receptor Activator (CERA) erythropoietic agents and psychotropic agents 
were actually unsafe. 
Reasons given to explain doping use were “advantages in terms of physical performance” (23, 
57,5%), “results achieved in a short time” (16, 40%), “good results during the competition” 
(15, 37,5%), “because it’s a common habit" (3, 7,5%) and other (2, 5%).  
Opinions about doping prevalence significantly varied according the participants if it was 
considered cycling in general and non professional cyclers instead their own team (100%, 
97,5% or 17,5%, respectively; p<0,001); the opinion about the degree of diffusion 
significantly differed as well (table 6). 
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Sources of information 
As presented in table 7, the several kind of sources of information were differently 
represented (p<0.0001) if the topic was doping instead of medications or DS. Indeed, in the 
last two cases, the prevalence of the different sources was quite homogeneous and did not 
statistically differ. In particular, the main sources of information were for drugs and DS the 
“specialized doctor” in 90,0% and 74,4%, respectively, while in the case of doping were 
principally represented by internet (82,5%) and newspapers/radio/tv (60%).  
 
Correlations 
No relationship between socio-demographic or anthropometric pattern were found with drug 
as well as DS use (not shown) or with doping knowledge. 
The knowledge of doping (evaluated as the ability to name prohibited substances as well as to 
identify doping agents) was significantly related with the number of drug used (r2=0.1614; 
p=0.01) but not with DS (r2=0.0068; p=0.61). 
 
Discussion 
To our best knowledge, this is the first study investigating the use of DS and medicines in 
young elite cyclists and its relationship with knowledge and attitudes towards doping. 
Participants were all young (age range: 19-23 years), healthy and with good instruction levels 
(97,5% with at least secondary school degree), which raise even more concern on our results. 
Moreover, our findings show the occurrence of extremely high use of prescription drugs as 
well of DS. 
Indeed, the use of prescription drugs was higher than the prevalence reported in literature (44-
61%) (Tscholl et al., 2008; Huang et al., 2006), since 75% of the sample have used at least 
one drug (up to 5) in the last 3 months, with a mean of almost 3 drugs/subject. These findings 
are considerably high if compared to OSMED report according to which around 50% of the 
general Italian male population of the same age (15-24) have used at least one drug per year 
(rapporto OSMED 2009). 
According to our results the most popular class of drugs was represented by NSAIDs whose 
prevalence was similar to those observed in other surveys (33-38%), involving one third of 
the sample. This high prevalence may reflect conditions such as musculo-skeletal 
inflammation, overuse syndromes (tendinopathies) and the of pain relief for a variety of issues, 
which are quite common in endurance sports such as cycling (Huang et al., 2006:). Hard, 
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prolonging training loads without a sufficient recovery time may concur to these conditions 
and consequent NSAID use (Alaranta et al., 2008; Thuyne & Delbeke 2008; Tsitsimpikou et 
al, 2004; Huang et al., 2006; Corrigan et al., 2003) and especially top athletes have been 
reported to have a higher intake of medication than non-competing athletes (Dascombe et al., 
2010; Tscholl et al., 2008).  
ATC group B was the most common prescribed in our sample, in nearly three quarter of the 
subjects, a prevalence considerably far from the general population (less than 5%; OSMED 
report). If considered alone, iron use is mentioned as medication or a DS in nearly 30% or 
15% of the subjects respectively, prevalence that are in accordance to those of around 20% 
reported in literature (Huang et al., 2006).  
 
The high proportion of non-medical reasons for use of prescription drugs underlines the risk 
of inappropriate and excessive use of medications that could increase the risk of adverse drug 
events and interactions (Suzic Lazic et al., 2011). This also go in pairs with the pattern of DS 
use. 
Indeed the data of the present study are similar to previous works (75-90%; Suzic Lazic et al., 
2011; Dascombe et al., 2010) suggesting that the majority of elite athletes consume DS since 
almost all surveyed subjects (98%) have used at least one. Vitamins and minerals were the 
most commonly used DS in sports in general (50-63%; Huang et al., 2006; Lazic et al., 2011; 
Tsitsimpikou et al., 2004; Froiland et al., 2004; Sobal & Marquart, 1994), while in our sample 
of élite cyclers, aminoacids (34%) were the preferred substances. 
DS were mainly used with a cyclically pattern, principally for a dietetic integration and the 
60% of the users perceived benefits. Performance enhancement, extra energy supply, 
maximise recovery, nutritional deficiency, prevention of illness and to maintain health are 
major reasons offered to justify DS use (Dascombe et al., 2010; Huang et al., 2006; Froiland 
et al., 2004).  
The present study underlines the widespread perception of DS as substitutes to normal, well-
balanced diet as well as of significant benefits associated with dietary supplementation. 
Almost 70% of our sample was satisfied by DS use, however, though some DS could enhance 
the athletic performance, the scientific evidence confirming this benefit are lacking (Lazic et 
al., 2011; Tscholl et al., 2008; Baylis et al., 2001; Telford et al., 1992).  
Moreover, DS may present unwanted side effects starting from the micronutrient levels that 
exceeds the safe upper level to the interactions with concomitant medications (Sundgot-
Borgen et al., 2003). In addition, DS can be a source of unintentional doping, since some may 
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contain unlabelled substances that are included in the List of Prohibited Substances of the 
World Anti-Doping Agency (Geyer et al., 2008; de Hon & Coumans, 2007; Van Thuyne et al., 
2006; Pipe & Ayotte, 2002). The risk is particularly high for products with lack of controls 
such as coming from internet sales (Fouillot, 2004). Moreover the consumption of DS has 
been related with a higher propensity of positive doping violations (Lazic et al., 2011; 
Dascombe et al., 2010; Wiefferink et al., 2007; Papadopoulos et al., 2006).  
 
Doping 
A limited knowledge about doping agents was observed in our sample, considering the low 
average of doping agents spontaneously named (3 per individual) or recognized from the list 
(50%). As expected, the most popular were the erythropoiesis stimulating agents (though 
Hematide was known by a few percentage, 18%, and recognized as a doping agent only by 5 
out 40 cyclers), common banned substances used in cycling (Lentillon-Kaestner et al., 2011). 
The other substances, though spontaneously mentioned (table 4) by a few number of athletes, 
were mainly represented by GH (61%), stimulants (10%), testosterone or other anabolic 
steroids (10% or less). Moreover, less than 10% of the sample mentioned prescription drugs 
(insuline and corticosteroids, in 8 and 5%, respectively) as potential doping agents, while, for 
istance antiasthma and diuretics or other masking agents were not present in table 4. This 
restricted knowledge may be also observed within the list of doping substances recognized 
(Table 5), where, for instance, salbutamol was considered as doping by half of the cyclers and 
albumine  probenecid, a masking agent, only by 9 and 2 out 40, respectively.  
Moreover, sildenafil as well as tramadol were erroneously believed as banned substances. 
Pseudoepherdrine/ceterizine, commonly used for rhinitis and allergy, was known by half of 
participants and was considered as doping by 5% of the athletes. Noteworthy, the year of the 
survey, pseudoephedrine was simply included in the Monitoring Program, while, starting 
from 2010, it has been considered by WADA as a prohibited substance.  
The non-medical sources as the main origin of information about doping should be 
responsible for this partial and sectorial (i.e. used in cycling) knowledge about doping.  
However, though the main source of information both for drugs and DS, differently form 
literature (teammate or the coach; Juhn et al., 2003) was reported to be the specialized doctors, 
one omeopathic product (damiana compositum) was taken for a drug as well as a DS, not all 
the prescribed drugs were clearly specified (i.e. antibiotics) and 6 DS were included in the list 
of drug used.  
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These features reveal a certain confusion about the terminology and, together with the 
findings concerning doping knowledge previously discussed, underline the risk for 
unintentional doping using faked DS, prescribed medications or drugs used with non-medical 
indication (i.e. suggested by a teammate or by the coach). 
95% of the cyclists were aware about the risk of doping, while 5% tried to minimize the risk 
of doping restricting it to some agents such as erythropoiesis stimulating and psychotropic 
agents. 
Moreover, an apparent uneasiness when asked to express personal opinions about the 
occurrence of doping in cycling was observed in our sample, since the athletes declared that 
doping was widespread in cycling in general and at amateur level, however, when referring to 
their own team, the denial policy was extremely diffused since only 17,5% admitted its 
diffusion in their team. Indeed, although, anonymity may increase the truthfulness of the data 
collected, the limit of our questionnaire survey is that data are self-declared. 
Interestingly, medications and DS mainly used (group B and iron), together with frequent 
drug use indications such as “anemia” as well as “to maintain hematocrit”, underlie  the 
particular attention towards hematocrit values within cyclers. Moreover, the significant 
correlation between use of prescription drugs and doping knowledge (especially represented 
by erhytrhopoiesis stimulating agents, very common in cycling), fatherly suggest that higher 
medication-users were potentially closer to doping risk. 
 
Conclusions  
The collected data confirms that a large number of athletes use  DS in hope of improving 
performance, though often uncritically, despite the lack of evidence of their efficacy and the 
recognition that such practices may carry risks (toxicity issues, drug interactions, possibility 
of “inadvertent” doping). 
In addition, superficial and “hematic-oriented” doping together with a potential hidden use, 
suggested by “denial policy” have been observed in our sample.  
The results of the present study, therefore, provide the basis for direct interventions aimed at 
increasing the knowledge and awareness of the risks in doping in younger cyclers through 
educational and preventive programs. Indeed, nowadays, according to some authors, doping 
practice in cycling has become more individualized and less institutionalized one. Cyclists, 
therefore, have been given more power in the choice to use doping agents, with less 
involvement of the physicians, with a progressive rising of underground market such as 
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internet (Lentillon-Kaestner et al., 2011). Moreover, educational programs should also include 
DS and prescripted medications, (since they are strictly related to a higher propensity towards 
doping) as well as the consequences of their inappropriate use such as adverse reactions and 
involuntary doping. 
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Tables 
 
Table 1. Anthropometric and socio-demographic features of the sample population. 
 Total  
 mean±SD (range) 
Age 20.7±1.3 (19-23) 
BMI (kg/m2) 21,1±1,0 (19.5-22.9)
 
Hours/week 21.8±4.3 (14-30) 
Started cycling (years) 11.1±3.2 (4-17) 
 
 
Education  
Primary school 1 (2,5) 
Secondary school 38 (95.0) 
Bachelor  1 (2.5) 
 
 
Non students 24  (60.0) 
Students 16 (40.0) 
 
 
Total 40 (100) 
 42 
Table 2. Pattern of drug prescription according to the ATC classification system. 
ATC Drug Drugs  Users  
  N % n % 
A*  11 13,1 9 30,0 
A11AA Multivitamins with minerals 1 1,2 1 3,3 
A11DB Group B vitamin 4 4,8 4 13,3 
A11GA01 Vitamin C 1 1,2 1 3,3 
A11JA Combinations of vitamins 5 6,0 5 16,7 
      
B  31 36,9 22 73,3 
B03AA07 Ferrous sulphate 7 8,3 7 23,3 
B03AB19 Sodium ferrigluconate 2 2,4 2 6,7 
B03BA01 Cyanocobalamin 11 13,1 11 36.6 
B03BA51 Cyanocobalamin combinations 7 8,3 7 23,3 
B03BB01 Folic acid 4 4,8 4 13,3 
      
J*  1 1,2 1 3,3 
J01 Antibacterials for systemic use 1 1,2 1 3,3 
      
M  8 9,5 8 26,7 
M01AE03 Ketoprofen 5 6,0 5 16,7 
M01AX17 Nimesulide 3 3,6 3 10,0 
      
N  7 8,3 7 23,3 
N02AX02 Tramadol 1 1,2 1 3,3 
N02BA01 Acetylsalicylic acid 5 6,0 5 16,7 
N02BE01 Paracetamol 1 1,2 1 3,3 
      
R  3 3,6 2 6,7 
R03CC02 Salbutamol 1 1,2 1 3,3 
R05CB01 Acetylcysteine 1 1,2 1 3,3 
R06AE09 Levocetirizine 1 1,2 1 3,3 
      
V  23 27,4 20 66,7 
V03AB32 Glutathione 19 22,6 19 63,3 
V03AF04 Calcium levofolinate 4 4,8 4 13,4 
      
Total  84 100 30 100 
* information supplied with the questionnaires did not allow identification of individual drugs  
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Table 3. List of dietary supplements used 
 Products Users 
 N % n % 
Aminoacids 37 34,3 28 71,8 
Hydro saline supplement 36 33,3 28 71,8 
Vitamins 19 17,6 19 48,7 
Iron 6 5,6 6 15,4 
Caffeine 5 4,6 5 12,8 
Proteins  2 1,9 2 5,1 
Ergogenic products 1 0,9 1 2,6 
Total 108 100 39 100 
 
 
Table 4. List of substances spontaneously mentioned as doping agents 
Substance N % respondents 
Erythropoietin  32 84,2 
Growth hormone  23 60,5 
CERA 26 42,1 
Amphetamine  10 26,3 
Testosterone 10 26,3 
Gonadotropin 5 13,2 
Nandrolon 5 13,2 
Ephedrine 4 10,5 
Insulin 3 7,9 
Anabolic steroids 2 5,3 
Corticosteroids 2 5,3 
Tramadol*  2 5,3 
Cocaine  1 2,6 
Corticotropin 1 2,6 
Methamphetamine 1 2,6 
Sildenafil* 1 2,6 
* non doping agents 
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Table 5. List of substances to be recognized and discriminated as doping or non doping 
(defined according the WADA list 2009)* 
 
Agents Recognized  Considered  as doping 
 N % N % 
Doping agents     
Growth hormone 39 97,5 39 100 
Testosterone 39 97,5 39 100 
Amphetamine 39 97,5 37 94,9 
Cocaine 33 82,5 28 84,8 
Ephedrine  32 80 30 93,8 
Human chorionic gonadotropin 28 70 27 96,4 
Nandrolone 24 60 24 100 
Salbutamol  23 57,5 21 91,3 
Methadone  19 47,5 16 84,2 
Albumin 17 42,5 9 52,9 
Corticotropin 7 17,5 7 100 
Hematide 7 17,5 5 71,4 
Probenecid  5 12,5 2 40,0 
Phenmetrazine  2 5,0 2 100 
     
Non doping agents     
Paracetamol 37 92,5 0 0 
Nimesulide 29 72,5 0 0 
Tramadol 25 62,5 6 24,0 
Pseudoephedrine*/cetirizine 20 50,0 1 5,0 
* Pseudoephedrine, included in the monitoring program in 2009, has been considered doping 
agent by WADA since 2010. 
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Table 6. Opinion about use and diffusion of doping in cycling. 
Does doping occurs in... cyclers 
in general? 
(A) 
non-professional 
cyclers? 
(B) 
your team? 
 
(C) 
P values 
 n % N % n %    
 40 100 39 97.5 7 17.5    
       A 
vs 
B 
A vs C B vs C 
       0.08 <0.0001 <0.0001 
- "a few" 0 0 0 0.0 6 85.7    
- "somewhat" 14 35 21 53.8 1 14.3    
- "a lot" 23 57.5 18 46.2 0 0.0    
- "every one use it" 3 7.5 0 0.0 0 0.0    
 
 
Table 7. Sources of information for drug use, DS and doping 
 
Drugs 
(A) 
DS 
(B) 
Doping 
(C)  P values  
Sources % % % A vs C B vs C A vs B 
    <0.0001 <0.0001 0.47 
Trainer 6.7 15.4 15.0    
Pharmacist 3.3 12.8 5.0    
Newspapers/radio/TV 3.3 7.7 60.0    
Internet 13.3 15.4 82.5    
GP 23.3 15.4 10.0    
Specialized doctor 90.0 74.4 20.0    
Relatives/friends 6.7 15.4 35.0    
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Dietary supplements and anabolic substances in recreational 
sports 
 
 
Abstract  
 
Purpose: To collect data concerning use and knowledge of dietary supplements (DS) and 
anabolic substances (AS) among recreational athletes. 
Methods: Anonymous semi-structured questionnaires were distributed to generic fitness 
centre visitors and to bodybuilders. Prevalence, knowledge, attitudes and factors related to DS 
or AS intake were investigated. Selected bodybuilders admitting the use of AS underwent 
anonymous interview. 
Results: Among fitness centre generic visitors, 50 respondents aged 29.5±6.5 years (94.0% 
males, main activities: fitness, 40% and bodybuilding, 24%) reported DS use in 82.0% cases 
(2.4±1.3 DS/subject), mainly aminoacids (36.7%) and proteins (28.6%). 78.6% perceived DS 
use as satisfactory. No association was observed between socio-demographic features and 
use/attitudes towards DS. DS intake was considerably higher in bodybuilding (3.1±1.5 vs 
2.0±1.5 DS/subject; P<0.05). 
Among bodybuilders, 31 (83.9% males) aged 31.2±7.7 years, completed the questionnaire. 
54.8% of respondents (100% males, P<0.03 vs females)  
named at least one AS (2.9±1.6/subject), mainly testosterone and  
nandrolone. In a list of 21 AS-related adverse reactions, 13.1±5.2  were not recognized. 
Although none declared AS use, some (25.8%) admitted previous consideration. 
According to anonymous interviews to 7 admittedly AS users (100% males; age 36.3±8.2 
years),  “cardiovascular problems” and “hepatotoxicity” were the main reported (57.1%) risks 
to AS use.  Expected benefits (appearance/performance improvement) were satisfied and only 
two mild adverse reactions were reported. 
Conclusions: DS are widespread and perceived as useful within our sample of recreational 
athletes. Results confirm the widespread interest in DS and in AS among bodybuilders, who 
however seem to have very limited and selective perception of AS-related risks. 
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Introduction 
Over the last decade, performance- and image-enhancing substances, such as dietary 
supplements (DS) as well as anabolic substances (AS), have been increasingly used also 
outside the elite world of sport (Guyda 2005; Huang, 2006; Kanayama 2001). 
DS use appears to be spread also in the general population and, especially in gyms among non 
professionals sportsman (Guyda, 2005), since they do not require prescription and are 
available with claims ranging from for self-care, to increase endurance, energy and decrease 
fatigue, to gain muscle mass, to lose fat, etc. (Braun 2009; Tsitsimpikou  2009; Tscholl 2008; 
Sobal 1994; Molinero 2009). Though the intense marketing and promotion, only a few 
rigorous studies have been performed, therefore, the advantage of supplementation on 
sporting performance is controversial and the actual efficacy of most DS available on the 
market has been never assessed (Dascombe 2010; Bishop 2010; Maughan 2007). A balanced 
diet usually effectively meets all the needs of physical exercise, therefore, DS are usually 
unnecessary if not dangerous, due to inadequate product labelling, presence of contaminants 
or undeclared substances (such as anabolic androgenic steroids) (Geyer 2008; de Hon 2007; 
Van Thuyne 2006; Sundgot-Borgen 2003; Pipe 2002). 
DS consumption has also been found to increase the likelihood of subsequent use of illicit 
substances, mainly represented by AS (Suzic Lazic 2011; Dascombe et al., 2010; Wiefferink 
et al., 2008; Papadopoulos et al., 2006). Indeed, the prevalence of drugs such as AS to 
improve sports performance and body appearance in fitness sports appears alarmingly high, 
ranging from 5 to 14%, and represents, thus, an issue of extreme relevance for the health care 
system (Simon 2006; Korkia 1996; Korkia 1997; Kanayama 2001; Striegel 2006; Leifman 
2011). The current knowledge about the actual use and attitudes towards DS and AS among 
recreational athletes, such as fitness centres visitors, is however scarce (Leifman 2011; 
Tsitsimpikou 2011; Bojsen-Møller 2010; Oliver 2008; Chłopicka  2007; Papadopoulos 2006; 
Morrison 2004). Fitness centres visitors nonetheless represent a large and heterogeneous 
population, and educational and preventive measures aimed at reducing the improper use of 
substances in such population are therefore of critical importance at the individual as well as 
at the societal level. 
We hereafter report the results of a series of independent and complementary studies among 
people attending fitness centres, aimed at assessing prevalence, knowledge, attitudes and 
factors associated to the use of DS and at surveying knowledge and risk perception related to 
AS use. As a whole, we observed a widespread interest in DS and AS by fitness centre 
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visitors and in particular among bodybuilders, as well as a very limited and selective 
perception of related risks. The present results may help planning educational programmes 
specifically targeted to carry out effective preventive strategies.  
 
Materials and methods  
Informed consent was obtained from all participants and the surveys were conducted in 
accordance with ethical research guidelines. 
 
Study 1 - Dietary supplements 
In January 2009 anonymous semi-structured questionnaires were distributed to clients of a 
gym located in Northern Italy. The three sections in the questionnaires allowed to gather: 
- socio-demographical characteristics: age, sex, body mass index (BMI), education, 
place of living; 
- information about physical activities: main physical activity, role (athlete, trainer), 
level, from how many years, other physical activities and total time devoted to sport; 
- information about the use of DS: knowledge, use in the last three months and kinds of 
DS, expected and obtained benefits, sources of information and of supply. 
 
Study 2 - Anabolic substances 
The study included non-professional bodybuilders in another fitness centre in Northern Italy. 
Surveyed subjects were given an anonymous semi-structured questionnaire to collect the 
following data: 
- socio-demographical characteristics: age, sex, education, place of living; 
- physical activity performed, other physical activities and level and total time devoted 
to sport; 
- knowledge about AS: acquaintance, source of information, risk perception 
(seriousness and adverse reaction known within a list), opinion about the diffusion 
among bodybuilders, reason for use and personal use. 
- Drug used in the last three months: reasons and source for advice. 
 
Study 3 - Subjective reports from AS users 
This study, performed in the same fitness centre of study 2, was based on a different group of 
bodybuilders who, during preliminary contacts, had admitted current or previous use of AS. 
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The semi-open face-to-face interviews were conducted by one of the authors (GP), who has 
many years of experience in training at fitness centres and has a good understanding of the 
bodybuilding environment. The anonymous interview was carried out as a conversation in 
which open-ended questions were used to cover the following areas: 
- Socio-demomographic data (age, kind of work) 
- bodybuilding (from how many time they started and level of competition) 
- knowledge of AS (definition, source of information, risks) 
- use of AS (kind of AS used, reasons, benefits, adverse reactions) 
- use of DS and drugs 
 
Statistical analysis 
Collected data were recorded in a digital archive (MS Excel, Microsoft Inc., USA) and 
analyzed through a descriptive approach. Anthropometric data (height and weight) were 
summarized as body mass index (BMI, kg/m2). Statistical significance was examined using 
the χ2-test distribution, the unpaired Student’s t-test, ANOVA or the Pearson correlation test, 
as appropriate. Results are shown as mean±standard deviation (SD). 
 
Results 
 
Study 1 
 
Subjects 
A completed questionnaire was provided by a total of 50 respondents, principally males (47, 
94.0%), with a mean age of 29.5±6.5 years (range: 18-44 years), and a mean BMI of 24±2.1 
kg/m2 (range: 19.7-30.1). Characteristics of the study population are represented in table I. 
 
Sport activities 
Sports were played at amateur level in the majority of the cases (41, 82.0%; 40 out 47 males, 
85.1%; 1 out 3 females, 33.3%) and there were only 5 (10.0%) regional professionals (all 
males) and 4 (8.0%) national professionals (2 out 47 males, 4.3%; 2 out 3 females, 66.7%).  
Hours/week globally devoted to physical activity were 9.6±6.1 (range 3-35), 9.1±5.2 (3-35) in 
males, 18.6±6.7 (6-35) in females. Main sports performed were fitness (a total of 20, 40.0%; 
males: 19 out 20), bodybuilding (12, 24.0%; all mal
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had been practised since 10.0±7.5 years (range: 10-25), 10.1±7.6 (1-25) in males, 8.8±7.3 (1-
13) in females. Participants were principally athletes (44 subjects, 88.0%; 40 out 47 males, 
85.1%; 1 out 3 females, 33.3%), while only 12.0% (all males) were trainers. 44 subjects 
(88.0%) practised at least another sport (2.0±1.1 sports/subject; range: 1-5), 41 males (87.2%) 
(2.0±1.1 sport/subject; range: 1-5) and all the females (1.3±0.6 sport/subject; range: 1-2). No 
significant differences in sport activities were observed between males and females. 
 
Dietary supplements use and knowledge 
The majority (42, 84.0%) of the subjects (40 males, 2 females) used a total of 98 (2.3±1.3 
DS/subject; range: 1-6)  principally aminoacids (36, 36.7% of total DS) proteins (28, 28.6%) 
and creatine (13, 13.3%). DS intake was defined as continuous by 31 subjects (73.8%) and 
occasional in the remaining cases. No significant differences were noticed in the type of DS 
used among different sports played. DS were usually purchased at specialized shops by 21 
users (50.0%) , fitness centre (11, 26.2%), acquaintances (11, 26.2%), internet (4, 9.5%), 
drugstores (2, 4.8%). DS were used principally upon advice from trainer (28 cases, 66.7%), 
relatives/friends (14 cases, 33.3%), physician (6, 14.3%), self-prescription (5, 11.9%),  
pharmacist (3, 7.1%). 
The expected benefits were generally perceived as satisfied (78.6%), among these, “quicker 
recovery” (26 users, 61.9%) and “better performance” (17, 40.5%) were the most commonly 
reported. Moreover, 76.2% of the users were prone to take them again. 
A satisfactory definition of DS was given by 11 (22.0%) of participants. 
According to the 8 non-users of DS, “DS are necessary only for professional athletes and are 
related to a deep interest for health” for 5, “are useless or even dangerous” for 2 and “useful 
for deficiencies of the modern diet” for one. 
 
Correlations  
No association was observed between age, sex, education, place of residence and knowledge, 
use or attitudes towards DS. DS intake was however significantly higher in subjects practising 
bodybuilding in comparison to fitness, the other most represented physical activity, as well as 
to the other physical activities taken as a whole (3.1±1.5 DS/subject vs 2.0±1.0 or 2.0±1.1 
DS/subject respectively; P<0.05). 
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Study 2 – Bodybuilders and AS 
 
Subjects 
31 subjects, 26 (83.9%) males, aged 31.2±7.7 years (range: 20-49), completed the 
questionnaire. Characteristics of the sample as well as data concerning physical activity are 
reported in table II. 
 
AS knowledge, risks and diffusion 
26 subjects (83.9%) were able to give a satisfactory definition of AS, however 23 (74.2%) 
identified AS only as doping agents, while only 3 (9.7%) knew also their clinical indications. 
17 (54.8%), all males (P<0.03 vs females), named 44 substances, 2.9±1.6/ subject (range: 1-6), 
principally testosterone (12, 27.3%) and nandrolone (12, 23.7%), followed by GH (5, 11.4%), 
stanozolol (4, 9.1%), methandrostenolone (3, 6.8%) and danazole (2, 4.5%). 6 non AS were 
also erroneously included in the list: EPO (2, 4.5%), cocaine (1, 2.3%), “proteins” (1, 2.3%), 
creatine (1, 2.3%) and cortisone (1, 2.3%). 
Though all the subjects declared to be aware about the potential risk due to the use of AS, 2 
(6.5%) believed that this risk was associated only to some of them. Among a fixed list of AS-
related adverse reactions, only 9.9±5.2 (range: 2-20) items were recognized as potential 
adverse reactions to AS and the most represented was testicular atrophy (25, 80.6%), followed 
by erectile dysfunction (24, 77.4%), myocardial ischaemia (23, 74.2%), liver cancer (22, 
71.0%), (Table III). 
Information concerning AS were collected from internet (17, 54.8%), trainer (15, 48.3%), 
media (14, 45.2%), acquaintances (5, 16.1%), pharmacist (1, 3.2%), or other sources (2, 
9.7%). 
According to 20 responders (64.5%), AS use was a widespread habit also among amateurs 
while for 9 (29.0%) it occurred only among professionals bodybuilders. Aesthetic reason is 
the main driver (28, 90.3%) reported for AS use, followed by the desire to get quicker results 
(21, 67.7%), to compete in a professional contest (13, 41.9%), to be advantaged in the 
competition (10, 32.3%), since many use them (4, 12.9%) or the risks are underestimated (1, 
3.2%). Although all the subjects denied having ever used AS, 8 (25.8%) admitted that they 
had considered the possibility.  
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Drug use 
8 (25.8%) declared having used a mean of 1.9±1.1 drugs in the last 3 months, a total of 15 
drugs, represented by NSAIDs in 7 cases (46.7% of drugs), antiasthmatics in 4 (26.7%), oral 
antibiotics in 3 (20.0%) and antiulcer in 1 (6.7%). Drugs were taken under the advice of the 
general practitioner (7, 87.5%), pharmacist (6, 75.0%), specialized doctor (3, 37.5%), trainer 
(2, 25.0%). 
 
Correlations 
With the exception of the ability to name AS, reported only by male subjects, no significant 
relationship between knowledge of AS and level of education and other socio-demographic 
characteristics or drug use has been found.  
 
Study 3 – Subjective reports from AS users 
7 bodybuilders, all male, age 36.3±8.2 years, admitting the current or past use of AS, 
underwent anonymous interviews about knowledge and use of AS, drugs and DS. 
 
Case 1 
Sociodemographic data and bodybuilding 
38 year old, had started bodybuilding 5 years before at non professional levels.AS knowledge 
“AS”, according to the subject, were “chemical products that help to increase body strength 
beyond the physiological possibility, some of them without increasing body mass”. 
He was aware of the risk for cardiovascular, liver, kidney, and prostate damage, and for 
impotence and alopecia. 
The reported sources of information were gym mates and trainer and, in particular, self 
documentation through internet. 
AS use 
He started AS when he was 35 with the goal to improve his body appearance. AS use was 
based principally on self-prescription and information collected through a specialized forum 
on internet, chatting with long-time AS users. 
He used several kinds of AS, included insulin and clenbuterol and 8 anabolic androgenic 
steroids (i.e. testosterone propionate, nandrolone, stanozolol, boldenone, trenbolone, 
drostanolone, metenolone, mesterolone) with a cyclical pattern (4-8 weeks). He had also used 
stimulants such as ephedrine. 
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He reports huge benefits such as an increase of muscular body mass of 20 kg and a 
consequent considerable improvement in power lifting of 100% were reported after he had 
started AS. Adverse reactions consisted only in mild acne. 
DS or other drugs use 
AS cycles were associated to proteins (3,5 g for Kg of body weight) and sometimes also to 
stimulants such as ephedrine. Antiestrogens and gonadotropins were used at the end of the 
cycles. 
 
Case 2 
Sociodemographic data and bodybuilding 
He was 26-years old and had started bodybuilding at non professional level at the age of 22, 
to improve his body appearance. 
AS knowledge 
AS were defined as substances that help to improve physical performances and muscular 
mass. The curiosity about AS has risen talking about them with some friends. He told to be 
aware that AS were related to some risks, but he mentioned only impotence and sterility 
admitting to have a limited knowledge about other potential adverse events. 
AS use 
He had started AS use the year before in order to improve his body appearance and to increase 
the muscular mass to be as fit as the colleagues were. Under a colleague’s supervision, he 
started to use anabolic androgenic steroids such as stanozolol, nandrolone, testosterone and 
trenbolone, with a cyclic pattern (for 8 weeks followed by a short stop). He reported that the 
expected benefits were fulfilled and did not notice any adverse reaction. 
DS or other drugs use 
During the AS cycle he used protein and ramified aminoacids. At the end of the cycle he used 
antiestrogens in order to preserve the testicular production of testosterone. 
 
Case 3 
Sociodemographic data and bodybuilding 
He was 42 years-old and had started bodybuilding at a non professional levels since he was 25. 
He worked as a trainer in a fitness centre 
AS knowledge 
According to the subject, AS were substances responsible for psychological addition since 
they allowed to go beyond normal physical limits. He started to talk about AS with some 
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friends and then with some who were recognized among his bodybuilders community to be 
“AS-experts”. He admitted that at the beginning he thought that AS were not responsible for 
the neoplastic transformation of a cell but were only able to increase the growing speed, then 
after years of AS use he had broadened the awareness about other potential adverse events (i.e. 
cardiovascular disease and renal or liver problems). 
AS use 
He used AS 20 years ago for a couple of year in order to achieve his ideal of physical image 
and due to the desire to be a part of a group of persons aiming to reach the same body 
appearance. Initially he used nandrolone, stanozolol, testosterone and GH, with a cyclical 
pattern following the indications of some friends and then of “AS-experts”. He reported some 
injuries occurred to shoulders and pectoral muscles but he did not put them in relation with 
AS use. 
DS and other drug use 
He reported aminoacids and proteins intake. Estrogens were used at the end of AS cycle 
 
Case 4 
Sociodemographic data and bodybuilding 
He was 41 years-old and started bodybuilding since he was 23, participated to several 
completion and worked as a personal trainer. 
AS knowledge 
The subject simply defined AS as “drugs”. He reported that AS was a quite usual topic among 
his bodybuilding mates. According to him AS presented several benefits while adverse events 
(i.e. gynaecomastia, hepatotoxicity) could be avoided using them with a “scientific criterion”. 
AS use 
He had used AS from the age of 23 to 35 in order to be ready for the competitions. Under the 
supervision of an “AS-trainer” he used testosterone, GH, insulin. According to him, he 
obtained only benefits (improvement of physical performance and of muscular mass) since he 
used AS with a “scientific criterion”. 
DS or other drugs use 
He used a wide range of DS: proteins, aminoacids, creatine, vitamin complex. Every cycle of 
AS was followed by gonadotropins and estrogens in order to restore the endogenous androgen 
production and to avoid gynaecomastia. 
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Case 5 
Sociodemographic data and bodybuilding 
He was 47, started bodybuilding since he was 25 and sporadically had participated in the past 
to competitions. He worked as a personal trainer. 
AS knowledge 
He defined AS as hormones that can be used by ingestion or by injection, that are able to 
increase androgens (responsible for muscular mass growth) as well as estrogens levels. His 
source of information were gym mates who were using AS. 
He was aware that AS use is related to the danger of cancer and cardiovascular problems. 
Since he knew their risks he said to have discouraged AS use by the athletes he followed. 
AS use 
He used AS for a few months (two cycles of AS) at the age of 35 under the supervision of an 
“AS-expert” in order to further improve his body image. He used testosterone, nandrolone 
and stanozolol for a 8 weeks cycle. He noticed an increase of physical and psychological 
power and in sexual desire and did not report any problem related to AS use. 
DS or other drugs use 
He had used DS at the end of the AS cycle “in order not to overcharge the liver”. 
 
Case 6 
Sociodemographic data and bodybuilding 
He was 25 years-old and practiced bodybuilding for 5 years at non professional level. 
AS knowledge 
He defined AS as hormones able to increase the muscular mass and widely used internet as a 
source of information. He reported to be aware of the risks related to AS use but did not go 
into details. 
AS use 
He started AS use 6 months ago since he was dissatisfied with his body image. He self-
prescribed 8/12 weeks-cycles of androgenic anabolic steroids (testosterone, nandrolone and 
stanozolol), but wished to be followed by an “expert”/”AS-trainer.” At the end of the cycle he 
used gonadotropins in order to restore the endogenous androgens synthesis. He observed 
considerable benefits such as an increase in physical performance and in sexual desire. He 
reported only an inflammation within the site of injection and, sometimes, a sudden change of 
mood and aggressiveness. 
DS or other drugs use 
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He reported DS intake, but did not go into details. He used antiestrogens, antiandrogens and 
betablockers in order to avoid AS adverse reactions. 
 
Case 7 
Sociodemographic data and bodybuilding 
He was 35 years-old and started bodybuilding since he was 17. He was a trainer for 
professional and non professional bodybuilders. 
AS knowledge 
AS was defined as an “ergogenic” aid to improve muscular mass. His first source of 
information was a mate who practiced bodybuilding at professional level. According to the 
subject, if used with appropriate schedule, AS use was beneficial. Liver and toxicity, 
cardiovascular problems, sterility were mentioned as potential AS adverse effects. 
AS use 
He had used cycles of androgenic anabolic steroids (nandrolone, stanozolol, boldenone, 
mesterolone) in the past in order to obtain results that were better than the simple training. He 
was initially supervised by some mates and then he started to look for information by himself 
through internet and books. He was satisfied from the use and did not observe any adverse 
reaction both in himself and on athletes he trained. 
DS or other drugs use 
He used progesterone and gonadotropins to restore spermatogenesis at the end of AS cycle. 
He reported the use of proteins. 
 
Discussion 
 
DS use and knowledge 
In our sample population of generic visitors of fitness centres the high prevalence of DS use 
(84%), principally represented by creatine and proteins/aminoacids, was similar to the few 
data available in literature (41-85%), strengthening the fact that even recreational athletes 
often try to push the limits of their sport performance (Oliver 2011; Tsitsimpikou 2011; 
Cholpicka 2007; Morrison 2004; Mason 2001). 
DS use may differ between sporting cultures (Cholpicka 2007) and, as expected, a 
significantly higher prevalence was observed among bodybuilders while, no association was 
observed between individual characteristics and attitudes towards DS, or DS use, perception 
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and knowledge. These data are consistent with the findings coming from direct interviews to 
bodybuilders using AS, in which all the subjects reported use of DS, especially proteins and 
aminoacids. 
DS intake, however, usually occurred acritically, without a full understanding of the potential 
benefits and risks associated, often due to a superficial knowledge, as observed in our sample 
where a satisfactory definition of DS was provided in just a few cases. 
Fitness centres per se often promote the use of DS through “corners” dedicated to information 
and sell. According to our results, the trainer was the main advisor for DS, while only a few 
respondents asked for the advice of qualified personnel, such as doctors or pharmacists. This 
finding is in agreement with published literature (Molinero 2009; Cholpicka 2007), and it is 
of some concern, since trainers in fitness centres are not required to have specific background 
in nutritional sciences to counsel athletes about actual effectiveness safety and legality of DS 
use. 
 
DS expected benefits and risks 
Expected benefits, mainly represented by a quicker recovery and an increased muscular 
mass/strength (in particular among bodybuilders), were satisfied in a large majority of the 
surveyed subjects. This finding is the likely result of the intense marketing campaigns of 
several DS, since very few studies have actually examined the performance advantages 
(Guyda, 2005). Indeed, the promotion of  many DS is often based only on hypothetical 
benefits coming from animal models, while evidence of advantages in humans is scarce and 
contrasting (Guyda, 2005; Telford, 1992) and only a few studies have explored benefits and 
safety data about the long-term use of DS (Schwenk, 2002; Tokish 2004; Philbin 2006). For 
instance, aminoacid supplementation has not been demonstrated to increase strength as well 
as endurance and appears unnecessary if one considers that in the typical athlete’s diet the 
protein balance meets the increased sport requirements (Jenkinson, 2008). Moreover, 
aminoacids may cause gastrointestinal adverse effects such as diarrhea and gastralgia 
(Jenkinson, 2008). As concerns creatine, another quite popular DS, scientific data concerning 
improvement of sport performance are contrasting (Jenkinson 2008; Mason 2001). Indeed, 
creatine intake may be detrimental due to the increase in body mass mainly related to water 
retention (Jenkinson, 2008; Williams, 1998). Although creatine supplementation does not 
seem to be associated to short-term health risks, long-term risks have not yet been assessed 
(Mason 2001). Moreover, cases of renal failure related to the association of several DS 
including creatine have been reported in literature (Thorsteinsdottir, 2006). 
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Besides contrasting evidence for benefits, the consumption of DS to enhance sports 
performance or to improve body appearance may, in itself, represent the first step to illegal 
preparations (Leifman 2011; Suzic Lazic 2011; Dascombe 2010; Wiefferink 2008; 
Papadopoulos 2006) since it may be associated with risky behaviours such as inappropriate 
use of medication, excessive intake of energy drinks, or illicit performance-enhancing drugs 
such as AS (Leifman 2011; Goyda, 2005). This possibility seems indirectly confirmed by our 
observation concerning the more intense use of DS in bodybuilders, who also admitted to 
have considered the possibility to use AS. 
In our sample 10% of DS source of supply occurred through internet. The raising market has 
opened up avenues for counterfeiting, therefore, these products are not necessarily produced 
in accordance with Good Manufacturing Practice. As a consequence, DS may contain 
unlabelled contaminants or illegal substances (Geyer 2008; de Hon  2007; Van Thuyne 2006; 
Pipe 2002) and the risk is consistently high for products with lack of controls such as coming 
from non institutional channels such as the internet sales (Fouillot 2004). Moreover, websites 
selling DS very often also sell AS and other illegal preparations, provide misleading 
information and are sources of deceiving practices (Cordaro et al., 2011). 
 
AS knowledge and attitudes 
Though the majority of bodybuilders who filled the anonymous questionnaire declared at least 
a secondary level education, collected data suggest only a limited knowledge about AS as 
concerns, for instance, the capacity to give a definition of AS or to name AS. Indeed, several 
non-AS were included among AS list, such as DS (proteins and creatine) commonly used by 
bodybuilders as well as drugs (cortisone and EPO), which may be used as doping agents, and 
cocaine. Noteworthy, available studies indicate that AS use is associated with other illicit 
drug use such as cocaine (Ip 2011; Simon 2006, Striegel 2006). 
AS users also exhibited a quite superficial knowledge of AS, with a specific interest in 
anabolic androgenic steroids as can be noticed in their answers. 
Not surprisingly, these substances were not only the best known AS but also the most 
commonly used by the interviewed bodybuilders. Indeed , in parallel to  DS, AS use, anabolic 
androgenic steroids especially, has consistently raised among non-competitive sports over the 
last decade, spreading in particular among bodybuilding (Melnik 2009; Mattila 2010; Guyda 
2005; Striegel 2006; Wieffrink, 2008 Leifman 2011; Agullò-Calatayud 2008; Simon 2006; 
Kanayama 2001; Korkia, 1996). According to several studies, the use of AS mainly occurs in 
males, is directly related to the degree of physical fitness (training years and frequencies) and 
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is higher in bodybuilders than in other fitness sports athletes especially, if they are preparing 
for a competition (Striegel 2006). In particular, the explicit use of anabolic androgenic 
steroids in fitness centres has been reported to be around 10% (Bojsen-Møller 2010). 
In agreement with published literature, in our subjects anabolic androgenic steroids represent 
the most widely used drugs by bodybuilders; steroid regimens usually include a mean of 3-4  
agents (both oral and injected drugs), usually taken in doses 5 to 30 times greater than the 
recommended therapeutic dose and involved cycles ranging 4 to 8 weeks followed by a 
withdrawal period (from 4 weeks to months) aimed at reducing the risk of adverse reactions 
(Kicman, 2008; Tahtamouni 2008; Perry 2005). As happened in our study, usually anabolic 
androgenic steroids are used in association with other AS such as peptide hormones (Ip 2011; 
Tahtamouni 2008; Striegel 2006; Perry 2005). Antiestrogens and gonadotropins are used in 
order to restore endogenous testosterone synthesis during these stops (Striegel 2006; Perry 
2005). 
 
Reason for AS use and perception of risks and benefits 
In agreement with the opinion gathered through the questionnaire and to literature data, all the 
AS users interviewed declared the central importance of the muscular body appearance (with 
both aesthetic and sport performance) (Melnik 2009; Striegel 2006; Cafri 2006).  
The dissatisfaction with one’s aspects as compared to the ideal standard flaunted by the media 
represents one of the main reason for starting bodybuilding and the consequent AS use 
(Cordaro 2011; Iriart 2009; Wieffrink 2008; Cafri 2005; Yesalis 2001; Brower 1994). In 
general, bodybuilders who are more dissatisfied with their body, are more prone to use AS 
(Goldfield 2009; Schwerin 1997). In our sample, even though the first group of bodybuilders 
denied the use of AS, some of them admitted to have considered it, suggesting the high 
pressure for promotion of these substances within bodybuilding world. One bodybuilder 
admitted during the interview that the dissatisfaction with his body image together with the 
desire to improve the self-image by increasing muscle mass drove him to AS use. 
Almost all the bodybuilders declared to be highly satisfied and to have achieved the expected 
benefits (such as higher physical performance and a considerable improvement in body 
image) after starting AS. 
A certain tendency to attribute several advantages to the AS use minimizing the potential risks 
has been observed in the present study. Questionnaire data revealed that only half of potential 
adverse reaction to AS were detected from a list (table III) and were most frequently 
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represented by sexual (testicular atrophy, 80.6% and erectile dysfunction, 77.4%), 
cardiovascular (74.2%) or liver (71.0%) problems.  
Indeed, the knowledge of potential adverse reactions were quite limited especially as regards 
cardiovascular and sexual problems. An alarming picture of underestimation clearly emerged 
among AS users since only two of them declared to have experienced adverse reactions, 
referred as mild and reversible in both cases. Moreover, another one user didn’t put in 
relationship a pectoral-shoulder injuries to AS use. In literature, the most commonly reported 
adverse effects due to the abuse of AS include impotence, acne, liver failure, myocardial 
infarction as well as psychiatric consequences (Kicman 2008; Casavant 2007; Brower 1994). 
However other adverse effects may be insidious psyco-physical adverse consequences of AS 
use may become evident with a considerable delay after long-term use of supraphysiologic 
doses and the subjects themselves may be unaware of such as damages to the cardiovascular 
system and, therefore, they may minimize the risks and there’s and intrinsic difficulty in 
collecting adverse effects of what is an underground activity (Kanayama 2008; Kicman 2008). 
Acne, reported by one of the AS users, according to literature, appears to occur in about 50% 
of anabolic androgenic steroids users and may represent, therefore, an indirect marker of 
abuse (Melnik 2007; Voelcker 2010). Questions concerning drug use were intended to detect 
potential adverse drug reactions due to AS which had required a pharmacological treatment. 
The use of antibiotic cream for acne may represent a clue of anabolic androgenic steroids use 
(Voelcker 2010). However, in our sample of bodybuilders, antibiotics were used in 3 cases 
but were represented by oral formulation.  
Moreover, as aforementioned for DS, counterfeit and poorly controlled products is a 
consistent risk for AS use since their source of supply is usually represented by the black 
market and internet (Cordaro 2011; Graham 2009).  
 
Source of information for AS 
In accordance to what observed in literature (Striegel 2006), source of information for AS 
principally reported were training colleagues, trainer and the gathering of pertinent literature 
(books, internet). The lower awareness of risks may be a direct reflection of the primary 
advisors’ knowledge of side effects. These data underline that the source of information may 
be poor qualified and even partial such as in the case of trainer who may be a user himself and 
may, therefore, suggest the AS use promoting the benefits and minimizing the risks, as 
implicitly admitted one of the trainer interviewed. Moreover, specialized internet forums may 
supply a large amount of information concerning the illicit use of AS in recreational athletes 
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enhancing the advantages (body image, muscular power) and minimizing or omitting the 
potential risks (Cordaro 2011).  
Concluding remarks 
One of the limit of  a survey of this nature is the risk of under-reporting. However, it has been 
demonstrated that information gathered through anonymous self-administrated questionnaire 
may be reliable (Laure 2007; Stone 2005). Moreover, in our present surveys the numbers 
were relatively small. This limitation however did not prevent from finding some significant 
correlations, moreover in particular direct interviews to bodybuilders who admitted AAS use 
provided relevant information about knowledge and attitudes in this high-risk population. We 
are now planning to increase the surveyed population and to investigate the possible 
relationship between AS and DS use and use of other illicit performance-enhancing agents. 
In conclusion, our findings highlighted that DS are quite popular among non-professional 
athletes, and especially in bodybuilders, since they are perceived as useful and harmless. 
General practitioners/caring doctors should be aware of DS intake, in order to ensure their 
proper use. In addition, trainers should acquire specific knowledge and education about the 
topic, as they appear to be the main advisors regarding the use of DS in gymnasiums. Due to 
the superficial knowledge concerning AS and the underestimations of their adverse reaction 
together with the higher prevalence than in the general population, fitness centres visitors, and 
bodybuilders especially, represent an appropriate target for informative interventions. 
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Tables 
 
Table I. Characteristics of the sample population included in study 1. 
 Total  Males Females 
 
   
Number of subjectsb 50 (100) 47 (94.0) 3 (6.0) 
 
   
Age (years)a 29.5±6.5 (18-44) 29.9± 6.7 (21-44) 22.7±7.2 (18-31) 
BMI (kg/m2)a 24±2.1 (19.7-30.1) 24.0±2.1 (19.7-30.1) 23.9±2.1 (20.1-22.3) 
 
   
Educationb    
 Primary school 3 (6.0) 3 (6.0) 0 (0.0) 
 Secondary school 35 (70.0) 33 (66.0) 2 (4.0) 
 Bachelor 11 (22.0) 10 (20.0) 1 (2.0) 
 Other 1 (2.0) 1 (2.0) 0 (0.0) 
Notes: a, mean±SD (range); b, n (%). 
 
  
Table II. Characteristics of the sample population included in study 2. 
 Total  Males Females 
    
Age a 31.2±7.7 (20-49) 31.6±7.6 (20-49) 29.2±12.0 (20-49) 
    
Bodybuilding    
 Hours/week a 5.7±3.8 (3-25) 5.8±4.1 (3-25) 5.2±1.3 (3-6) 
 Years started a  5.8±5.2 (0.5-20) 6.0±4.6 (0.5-17) 5.0±8.4 (0.5-20) 
 Total b 31 (100) 26 (83.9) 5 (16.1) 
    
Other sports    
Subjects b 10 (32.3) 9 (29.0) 1 (3.2) 
Number of other sports a 1.9±1.3 (1-5) 2.0±1.3 (1-5) 1 
    
Education b    
 Primary school 7 (22.6) 6 (23.1) 1 (20.0) 
 Secondary school 17 (54.8) 13 (50.0) 4 (80.0) 
 Bachelor  6 (19.4) 6 (23.1) 0 (0) 
 “Other” 1 (3.2) 1 (3.8) 0 (0) 
 Total 31 (100) 26 (100) 5 (100) 
Notes: a, mean±SD (range); b, n (%). 
 63 
Table III. Recognized adverse reactions due to AS use 
 N % 
Testicular atrophy 25 80.6 
Erectile dysfunction 24 77.4 
Myocardial ischaemia 23 74.2 
Liver cancer 22 71.0 
Hepatotoxicity 17 54.8 
Aggressiveness 17 54.8 
Voice deepening 17 54.8 
Hirsutism 15 48.4 
Clitoral hypertrophy 15 48.4 
Depression 14 45.2 
Thrombosis 12 38.7 
Prostatic hypertrophy 11 35.5 
Menstrual disorders 11 35.5 
Stroke 11 35.5 
Psychosis 10 32.3 
Tendon fraility 9 29.0 
Acne 8 25.8 
Dyslipidaemia 8 25.8 
Hypertension 7 22.6 
Gynaecomastia 5 16.1 
Growth deficit 4 12.9 
 
 
Table IV. Anabolic substances used by interviewed bodybuilder 
Anabolic substances N %AS %users 
Anabolic androgenic steroids 26 86,7 100 
Nandrolone 6 20,0 85,7 
Testosterone 5 16,7 71,4 
Stanozolol 5 16,7 71,4 
Boldenone 2 6,7 28,6 
Trenbolone 5 16,7 71,4 
Drostanolone 1 3,3 14,3 
Metenolone 1 3,3 14,3 
Mesterolone 1 3,3 14,3 
        
Other anabolic substances 4 13,3 42,9 
Insulin 2 6,7 28,6 
Clenbuterol 1 3,3 14,3 
GH 1 3,3 14,3 
    
Total 30 100 100 
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Herbal remedies use 
The use of HR appears to be widely used in industrialized world for several complains. HR 
are usually considered a safer alternative to conventional treatments, since they are perceived 
as “natural” and, therefore, beneficial or at least presumed to be free of risks. However, 
efficacy and safety of many of these products have not been clearly demonstrated. Recently, 
issues of contamination, adulteration and inappropriate labelling have raised (Mentha 2008).  
I have performed a review of the published literature concerning the use of Herbal remedies in 
the industrialized world, published in chapter 24 (“Herbal Medicines: Epidemiology of their 
Utilization—A Perspective on the Industrialized World”) of “Herbal Medicines: Development 
and Validation of Plant-derived Medicines for Human Health”, CRC Press. 
The use of HR is common among subjects suffering from chronic conditions due to unmet 
needs, a “grey area” that conventional prescribed therapy is not able to cover. Most patients 
do not discuss the use of HR with their health care provider, raising the risk of interactions 
with concomitant prescribed therapy. The risk is potentially high since up to 60% of herbal 
users are also under conventional treatment (Al-Windi 2004). Indeed, the number of reports 
concerning herbal-drug interactions as well as adverse effects are growing (Kennedy 2010).  
In “Use of herbal remedies among patients with multiple sclerosis: a nation-wide survey in 
Italy” I have investigated prevalence, knowledge and attitudes towards HR among multiple 
sclerosis patients. 
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Use of herbal remedies among patients with multiple sclerosis: a 
nation-wide survey in Italy 
 
Introduction 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system, with 
a prevalence about twice in women, and is the leading non-traumatic cause of disability in 
young adults in the Western World (Alonso et al., 2008; Pugliatti et al., 2006). The impact on 
patient’s quality of life is often significant and the social costs of MS are consistent because 
of the long duration and the peak in the prime of life, when families and careers are 
developing (Kobelt et al., 2006; Amato et al., 2002). Recent progress in the treatment of MS 
is remarkable, however, although new disease modifying agents may reduce the frequency of 
exacerbations and progression of disability, numerous unmet needs remains to be addressed 
such as efficacy (impaired effectiveness due to neutralizing antibodies, lack of therapeutic 
strategies options for progressive MS, etc.), safety (i.e. risks for malignancy and opportunistic 
infections) and adherence (approved treatments for MS are all parenteral) problems (Kieseier 
et al., 2009). Psychological problems/affective disorders (especially depression and anxiety), 
common in MS patients, represents other consistent unmet needs, since they require early 
diagnosis and appropriate interventions, not always provided (Gay et al., 2010). MS still 
results for most of patients in different degrees of disabilities requiring medical and non 
medical interventions. Thus, the burden of symptoms and distress often induce MS patients to 
seek for herbal remedies and, more extensively, for complementary and alternative medicines 
(CAM).  
The traditional knowledge of herbal remedies and their therapeutic applications, result of 
thousand years of experience, has been modernized in developed nations, evolving in the so-
called “Neo-Western herbalism” (Elvin-Lewis, 2001). Intercontinental travel, immigration 
and cross-cultural exchange, in general, have broadened the frame of reference of Western 
herbal medicine introducing the healing practices of other cultures. Echinacea, one of the 
mainly used plants, may be an example, since it originally came from North America. Herbals 
remedies are now widely available from many sources including health food stores, 
supermarkets, direct marketing, natural therapy clinics and pharmacies. 
Besides the purpose to promote general health/well being or for disease prevention (Singh et 
al., 2006), herbal remedies are also used in the treatment of several mild conditions (such as 
common colds, musculoskeletal problems, gastrointestinal symptoms, etc.) as well as 
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adjuvant in the management of chronic illness (cancer, cardiovascular diseases, etc.), where 
conventional treatment are often unfulfilling (Gardiner et al. 2007; Bardia et al. 2007).  
The use of herbal remedies have considerably risen since over the last decades in developed 
countries (Bardia et al. 2007), however, the actual prevalence remains undetermined due to 
the reduced number of epidemiologic studies. In particular, prevalence data (9-27%) among 
MS patients derive essentially from surveys dealing with a more extensive picture of CAM 
(Apel et al., 2006; Nayak et al., 2003; Apel et al., 2005; Leong et al., 2009; Marrie et al., 
2003; Olsen 2009; Yadav et al., 2006). Moreover, the rate of disclosure to the caring 
physicians is often low. Therefore, the use of herbals, so far scarcely investigate among MS, 
poses several challenges such as interference with conventional drugs as well as tolerability 
issues.  
In the current study we explored prevalence, knowledge and attitudes (why they are chosen, 
with which purpose,  how effective are perceived by users, etc.) towards herbal remedies. In 
addition, we evaluated the clinical as well as socio-demographic factors related to herbal use. 
Use and attitudes towards CAM have been also investigated. 
 
Methods 
 
Study design 
The present study was a nation-wide observational multicentric survey conducted from 
January’08 to June’09.  The study was previously submitted and approved by the Ethics 
Committees of each centres and an informed consent was obtained by each patient before the 
inclusion in the study. 
 
Patients and setting 
Patients suffering from multiple sclerosis (MS) according to the revised criteria of McDonalds 
(Polmann et al., 2005) were enrolled in 14 Italian reference centers for MS. MS outpatients 
consecutively attending a Neurological Clinic, accepting to participate to the interview, were 
administered a questionnaire which they could either complete in the ambulatory, with the 
help of a nurse, or take it at home and send it later through a addressed stamped envelope.  
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Questionnaire 
The questionnaire, anonymous with open as well as multiple choices questions, was 
structured into five section devoted to the collection of the following data: 
I. socio-demographic (age, sex,  marital status, education, occupation, residence) 
II. clinical features (age at the diagnosis, clinical self-reported disability, see below) 
III. pharmacological treatment in the last six months (for SM, for adverse reactions due to 
SM treatment, for other diseases) and rate of satisfaction 
IV. use and attitudes towards herbal medicine (use in the last six months or at any time in 
the past for MS, to treat diseases not related to MS, kind of products used, rate of 
satisfaction, occurrence of adverse reactions during the use, place of purchase, 
suggestion, reasons for using herbals and disclosure to the caring physicians about it) 
V. use and attitudes towards other complementary and alternative medicine (CAM) (use, 
kind, purpose, benefits obtained, suggestion and disclosure of the use to the caring 
physician). 
Self-reported clinical status was evaluated through a scale derived from the Kurtzke 
Expanded Disability Status Scale (Kurtzke, 2008) previously used in another study (Shinto et 
al.,  2005). For this purpose, subjects were asked to choose among six disease severity 
categories:  
1. None/minimal (no or minimal MS-related symptoms, no limitations in walking ability 
or in daily activities) 
2. Mild (noticeable MS-related symptoms, but no limitations in walking or in daily 
activities) 
3. Moderate (many MS-related symptoms that affect daily activities, no support needed 
to walk 1 block) 
4. Some support needed for walking (significant MS-related symptoms that limit 
physically demanding activities; support needed to walk) 
5. Walker/two-handed crutch (significant MS-related symptoms that limit daily 
activities, walking limitations: only short distances with a walker or two-handed 
crutches)  
6. Unable to walk (severe MS-related symptoms, restricted to a wheelchair or bed). 
Though the survey was not focused on the use of Cannabis sativa, a specific question about it 
was placed at the beginning of section IV, in order to avoid any potential bias in the 
subsequent answers about phytotherapy. 
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Two different and complementary typology of questions investigated the use of herbal 
remedies: an open one allowed the patients to freely name herbal remedies, while a close 
question was intended to recollect names through a list of medicinal herbs selected among the 
most popular according literature. 
 
The questionnaire was tested among 68 SM outpatients (72% women,  age (mean±SD) of 
38.5±11.5 years and suffering from MS since 9.5±6.6 years) consecutively attending the 
coordinating centre of Gallarate (VA). As a consequence, some changes (inversion in the 
order of some questions) were carried out to ameliorate the comprehension and compilation 
of the questionnaire. 
 
Data collection 
Between January and June’09 the collected data were inserted into a digital archive (MS 
excel). Records  were validated according to the International Quality Standard ISO 2859 
guidelines (ISO 2859-4:2002) and the database was considered suitable for analysis.  
Before the analysis each record was checked for intra and inter section coherence. In 
particular,  the reported products (drugs, herbs or other CAM) were carefully identified and, if 
necessary, reallocated into the appropriate sections. Patients failing to answer the questions 
about the use of medicines, herbals or CAM, but subsequently reporting the names of a 
specific product, were considered as users. 
 
To assess any potential difference among geographic areas, Italian region were grouped into 
five macro-regions according to the National Institute of Statistic (ISTAT) classification 
(http://www.istat.it/). 
 
Outcome measures 
The main outcome measure was the prevalence of patients using herbal products in the 
previous 6 months. Similarly to other surveys, we chose a six-month interval in order to 
balance the detection of the widest number of users with the highest reliability in the answers. 
In addition, we also evaluated the use at any time in the past to gain a more extensive picture 
of the herbal use. 
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Statistical analysis  
Collected data were analyzed with a commercial software (Stata10, Stata Corp, College 
Station, TX, USA). Descriptive statistics were used to estimate the prevalence and attitudes 
towards herbal use. We also used a logistic multivariate analysis to investigate any association 
between herbal use (in the previous 6 months and at any time in the past) and 
sociodemographical and clinical factors. 
 
Results 
 
From January’08 to June’09, 2419 questionnaires for MS were collected from 14 Italian 
Centres. According to the ISTAT macro-regions, 948 (39.2%) of them came from North 
West, 313 (12.9%) from North East, 70 (2,9%) from Central Italy, 463 (19.1%) from South 
and 625 (25.8%) from Isles. Socio-demographic and clinical features or the sample surveyed 
are presented in table 1. Respondents were principally female (68.8%), with a mean age 
(±SD) of 40.6±10.8 (range: 10-74) years and with a middle-high level of education (i.e. 13 
years devoted to study in 1006 cases, 45.7%). Patients were suffering from MS from 8.4±6.6 
years (range: 46-0) and in more than one half of cases the disease status was subjectively 
defined as “None/minimal” (1367 patients, 56.5%). 
 
Herbal use for MS or other diseases 
The actual or past use of Cannabis was declared by 280 (11.6%) of the participants; globally, 
2297 (95.0%) subjects answered to this question.  
The use of herbal remedies to treat MS was declared by 326 subjects (15.0%, 95% confidence 
interval [CI], 13.5-17.0%) and 134 of them (6.2%, 95% CI, 5.2-7.3%) used herbal remedies 
within the last 6 months. These products were used as adjuvant to conventional therapy 
(42.9%), to treat adverse drug reactions (29.8%) or as alternative to drugs (20.2%).  
The use of herbal remedies to treat other diseases than MS was declared by 762 patients 
(48.2%; 95% CI, 45.7-50.7%) and 262 of them (16.6%; 95% CI, 14.8-18.5%) used herbals 
within the last 6 months. In 226 cases (29% of herbal users) herbs were used to treat 1.7±1.2 
(mean±SD,  range 1-9) diseases, among which were mentioned: gastrointestinal diseases 
upper respiratory ways in 131 (17.2%) cases, sleep disturbances in 105 (13.8%), anxiety in 82 
(10.8%), genito-urinary infections in 60 (7.9%), migraine in 48 (6.3%), depression in 38 
(5.0%), osteoarticular pain in 38 (5.0%), cardiovascular diseases in 34 (4.5%), dermatitis in 
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34 (4.5%), dysmenorrhea in 31 (4.1%), allergy in 21 (2.8%), ocular inflammations in 17 
(3.1%), fever in 10 (1.8%). In 67 cases (8.8%) herbs were used for “other conditions”, mainly 
hydric retention (13, 1.7%) and weight problems (10, 1.3%).  
Globally, 862 subjects out of 2419 (35.6%) (38.0% of respondents, 95% CI, 36.0-40.0%) 
declared to have used in the last six month/any time in the past herbal remedies for MS or 
other diseases. 
 
CAM use 
The current or past recourse to other CAM was declared in 1028 cases (42.5% of sample), and 
consisted in vitamins/minerals (626, 60.9% of CAM users), other dietary supplements (498, 
48.4%), massages (259, 25.2%), homeopathy (200, 19.5%), acupuncture (92, 8.9%), and other 
CAM (111, 10.8%). 
Benefits were perceived by the majority of patients (82.2%, among which 40.1% were totally 
satisfied while 42.2% were partially satisfied by CAM use). Disclosure to the caring doctor 
was declared by 677 subjects (65.9% of the users). 
 
Predictors of the use of herbal products in the last 6 months 
Table 2 depicts the likelihood of herbal use by individuals’ sociodemographic and clinical 
features according to univariate and multivariate analysis. Women appeared to be more prone 
to use herbal remedies than men (OR= 1.69). The likelihood to use herbals increased together 
with the level of education (OR= 1.61 to 2.17). The use appeared to be influenced by the 
geographic area, being higher in the Northern Italy (OR= 1.50). CAM use as well as the 
perception of benefits from it, were other important determinants (OR= 3.57 and 6.25, 
respectively). The multivariate analysis of the use at any time in the past confirmed these 
results. No clinical features appeared to be related to the use. In addition, dissatisfaction with 
conventional treatment for diseases other than MS was related with the use of herbal products. 
 
Features of herbal use 
Among a total of 765 substances mentioned, 560 (73.2%) were properly herbal remedies. In 
particular, 385 subjects (44.7% of users) named at least 1 or more herbal products (1.5±0.9 
herbs/subject mean±SD; range: 1-5), among which the most popular (in at least 5 users) have 
been listed in table 2. Propolis (40, 4.2% of users), aloe vera (37, 4.3%), and valerian (31, 
3.6%), were the in the lead.  
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Substances other than herbal remedies, mentioned in 205 (26.8%) cases, were represented by: 
vitamins/supplements in 83 cases (10.8%), homeopathic remedies in 43 (5.6%), Bach’s 
flowers in 24 (3.1%), conventional drugs in 7 (0.9%), algae in 6 (0.8%), cosmetics in 3 
(0.4%), cannabis in 1 (0.1%). In addition Hebener therapy was named in 1 case (0.1%), while 
in 37 (4.8%) handwriting was illegible.  
Specific use of herbs was further explored by a second question in which the patients were 
invited to select if they had use one of the listed herbs (Table 4). Among the herbs in the list: 
ginseng (282, 32.7% among users), followed by Hypericum perforatum (122, 21,7%), 
liquorice (113, 13.1%) and Echinacea (105, 12.2%) were the most frequently selected. 
631 (73.2%) subjects were completely (36.2%) or at least partially (37%) satisfied by the use 
of herbal remedies. Benefits declared were represented by the complete remission of 
symptoms in 73 cases (8.5% of the users), improvement in 345 (40.0%), reduced intake of 
conventional drugs in 62 (7.2%) and “other” in 42 cases (4.9%). During the use of herbal 
products 44 patients (5.1% of the users) denounced the occurrence of new disturbances, 
among which the most frequent were the worsening of neurologic symptoms in 21 (2.4% of 
the users), followed by psychological symptoms in 9 (1.0%), gastrointestinal problems in 5 
(0.6%), arrhythmias in 3 (0.3%), fever in 2 (0.2%), rash in 1 (0.1%), hypotension in 1 (0.1%), 
flushing in 1 (0.1%), gastralgia during the use of devil’s claw in 1 (0.1%).  
Herbal products were purchased at the herbalist's shop in 462 cases (53.6% of the users), 
pharmacy in 373 (43.3%), supermarket /drugstore in 60 (7.0%). The 39 cases (4.5%) in which 
the term “other” was indicated are presented in table 4. 
Herbal remedies were used upon the advice of herbalist in 276 (32.0%) patients, 
acquaintances in 223 (25.9%), pharmacist in 134 (15.5%), general practitioner (GP) 131 
(15.2%), media in 53 (6.1%), internet in 53 (6.1%), caring neurologist in 24 (2.8%), 
alternative practitioner in 15 (1.7%), self prescription in 5 (0.6%), other specialist in 5 (0.6%), 
nutritionist in 4 (0.5%), nurse in 1 (0.1%). 361 users (41.9%) declared to have disclosed the 
herbal use to GP or to the caring specialist. 
The reasons for using herbal products were it was less toxic than conventional treatment for 
277 subjects (32.1% of users), it had been recommended for 164 (19.0%) it was effective for 
162 (18.8%), the purpose to follow a healthy lifestyle for 146 (16.9%), curiosity for 
alternative medicine for 126 (14.6%), inefficacy of conventional drugs for 39 (4.5%). 
In addition, 470 subjects had used regularly (83, 9.6% of herbal users) or occasionally (377, 
43.7%) herbal treatment before the occurrence of MS. 
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Discussion 
Italian MS patients are estimated to be around 57000 (http://www.aism.it). In this study 
almost 2500 SM patients were surveyed, representing a consistent sample, higher than most 
of other studies in patients suffering from MS or other chronic diseases. Moreover, the main 
outcome is devoted specifically to herbal than to CAM use. A herbal use for any purpose in 
more than one third of the MS patients surveyed denoted it was quite popular. In particular 
more than 6% and 16% of subjects had used herbal remedies the previous six months for MS 
or other diseases, respectively. This is in accordance with the prevalence observed among 
other group of MS patients (9-26%) (Apel et al., 2006; Apel et al., 2005 Nayak et al., 2003). 
In the latter part of the 20th century herbal medicine use, became a substantial and growing 
part of health-care behaviour in the industrialized world. The use of CAM, and herbal 
remedies in particular, seems to be higher among MS patients than in the general population 
(Olsen, 2009). Indeed, a considerable lower prevalence has been observed among Italian 
general population. In an Italian nationwide survey (nearly 80 thousands subjects interviewed, 
with a section reserved for CAM) performed in 1999, herbal users accounted for 5% of 
participants (Menniti-Ippolito et al. 2002). However, this lower prevalence may be influenced 
not only by the difference between the general population and MS subjects (chronic ill 
affected subjects), but also by the structure of that survey itself, which was not specifically 
devoted to herbal remedies. 
Interest in herbal remedies may be due to a dissatisfaction with conventional health care and 
the perception that those are safer than pharmaceutical drug  and may also reflect a desire for 
a personal control over oneself health to take a more active part in therapy and prevention of 
illness. In our study, the use herbal remedies was related with the choice to follow a healthy 
lifestyle, together with dissatisfaction with drug treatment. However, the tendency in our 
sample was not to give up conventional treatment in lieu of herbal remedies, but to use them 
as adjuvant to conventional therapy. 
Our findings are consistent with those of most studies among general population, since a 
typical herbal user presents the following features: female (OR 1.69), with a higher level of 
education (secondary school/university; OR 1.61-2.17), living in the Northern Italy (OR: 
1.50), being dissatisfied with the conventional treatment of diseases other than MS (OR: 
3.21), using and being satisfied by CAM (3.57 and 6.25, respectively) (Gardiner et al., 2007; 
Kelly et al., 2006; Wheaton et al., 2005; Al-Windi 2004; MacLennan et al 2002).  
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Although controversial, Cannabis use appear to be quite popular among subjects suffering 
from MS, especially to manage MS symptoms such as pain, spasticity, mood, tremors, fatigue 
or bladder dysfunction (Yaldav et al., 2006). In particular our sample showed a similar 
prevalence (12 %) to those (14-16%) obtained in other though smaller studies (Clark et al., 
2004; Martínez-Rodríguez et al., 2008; Chong et al., 2006). 
Our findings were similar to those of other large surveys as concerns the most commonly 
mentioned herbs (table 1) as well as the most commonly selected (table 2) ones (Gardiner et 
al., 2007; Singh et al., 2006).  According to the US 2002 National Health Interview Survey, 
the most commonly herbal products used were Echinacea (40%), ginseng (24%), gingko 
biloba (21%), garlic (20%), St. John’s wort (12%), peppermint (12%), ginger supplements 
(11%), soy supplements (9%), chamomile (9%), kava kava (7%), valerian (6%), saw palmetto 
(6%) (Gardiner et al., 2007) 
Similarly, the most commonly mentioned herbs among Canadian populations were: echinacea 
(27%), garlic (21%), gingko biloba (11%), herbal tea (6%), St. John’s wort (6%), ginseng 
(5%), flaxseed oil (4%), evening primrose oil (3%), devil’s claw (3%). (Singh et al., 2006).  
Though small differences concerning the less represented herbs, resemblances largely prevail 
if the most popular herbs, i.e. echinacea (for cold symptoms and to enhance the immune 
system), ginko biloba (to improve memory), ginseng (as an energy booster) and garlic (for 
hypertension and dyslipidaemia) are considered, suggesting a globalisation in herbal market. 
Our findings concur with previous studies regarding the disclosure to the health provider who 
is informed in less than half of cases, with considerable risks of adverse drug reactions an 
potential interferences with drug therapies. 
The knowledge of herbal medicine appears to be often inaccurate since caring physician has 
been reported to be rarely a source for information and certain degree of confusion in 
terminology has been observed; vitamins and supplements, homeopathic remedies and Bach’s 
flowers, for instance, were confused with proper herbal remedies. 
The level of satisfaction was high (more than 70%), and only in 6% of cases, new 
disturbances occurred; however they were mainly related to new sensitive symptoms or 
impairment of MS clinical picture, and only in one case the patient clearly related the 
disturbance occurred to the herbal remedies (gastralgia after using devil’s claw). 
Although, some data in literature suggest that CAM may be beneficial in the management of 
MS symptoms, the actual efficacy and safety of such therapies in MS have not been clearly 
established because of randomized clinical trials are scant and sample size usually small 
(Olsen, 2009). Herbal remedies, in particular are usually considered a safer alternative to 
 74 
conventional treatments, since they are perceived as ‘natural’ and, therefore, beneficial or at 
least free of risk. Therefore, the use of herbal products is a matter of concern for health care 
providers since the number of reports concerning herbal-drug interactions as well as adverse 
effects are growing (Kennedy et al., 2010). 
In conclusion, this large observational survey, among more than 4% of Italian SM patients, 
allowed the creation of the first database containing detailed information about the use of 
herbal remedies in Italian SM patients. The degree of involvement of the caring physician 
(source of information, disclosure) in herbal treatment appears to be scarce, with the potential 
risk of adverse reactions or interference with conventional treatments. The knowledge of 
socio-demographic or health features potentially related with the use of herbal products is 
clinically relevant since it may allow physicians to identify the most likely users and, 
therefore, to direct appropriate educational and other preventive interventions. 
 
 75 
Tables 
 
Table 1. Socio demographic and clinical features of the population surveyed 
 Overall N (%) Median (25-75); range 
Characteristics   
Age   
Years - 40 (33-48); 10-74 
Duration of the disease   
Years - 7 (3-12); 0-46 
Gender   
Male 729 (30.2) - 
Female  1665 (68.8) - 
Missing answer 25 (1.0) - 
Living   
With someone 2157 (89.1) - 
Alone 222 (9.2) - 
Missing answer 40 (1.7) - 
Marital status 
  
Single 712 (29.4) - 
Married/cohabiting 1481 (61.2) - 
Separated/divorced 175 (7.2) - 
Widowed  33 (1.4) - 
Missing answer 18 (0.8) - 
Education   
5-8 yrs 882 (36.5) - 
13 yrs 1106 (45.7) - 
>13 yrs 383 (15.8) - 
Missing answer 48 (2.0) - 
Occupation   
Yes 1442 (59.6) - 
No 959 (39.6) - 
Missing answer 18 (0.8) - 
Geographic Area   
Northwest 948 (39.2) - 
Northeast 313 (12.9) - 
Centre 70 (2.9) - 
South 463 (19.2) - 
Isles 625 (25.8) - 
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Table 2 Univariable and multivariable analysis of the predictors of the use of phytotherapy 
(part I) 
 
  Univariable  Multivariable 
Characteristics Herbal use N (%) OR (95% CI)  OR (95%CI) 
Age -    
Per year  0.99 (0.98-1.00)  1.00 (0.98-1.01) 
Duration of the disease -    
Years  1.00 (0.99-1.02)   
Gender     
Male 70 (10.4) 1[Reference]  1[Reference] 
Female  257 (16.4) 1.69 (1.28-2.22) ***  1.33 (0.98-1.82) 
Living     
With someone 287 (14.0) 1[Reference]  
 
Alone  35 (17.0) 1.23 (0.85-1.82)  
 
Marital status     
Single 100 (14.8) 1[Reference]   
Married/cohabiting 201 (14.5) 0.98 (0.76-1.27)   
Separated/divorced 21 (12.9) 0.85 (0.52-1.42)   
Widowed  4 (14.8) 1.00 (0.34-2.67)   
Education     
5-8 yrs 79 (19.3) 1[Reference]  1[Reference] 
13 yrs 167 (15.6) 1.61 (1.21-2.14)**  1.24 (0.90-1.71) 
>13 yrs 74 (19.9) 2.17 (1.54-3.06)***  1.44 (1.02-2.11)* 
Occupation     
Yes 211 (15.2) 1[Reference]  1[Reference] 
No 114 (13.2) 1.18 (0.92-1.51)  0.89 (0.66-1.18) 
Geographic Area     
Northwest 149 (16.5) 1[Reference]  1[Reference] 
Centre 17 (25.8) 1.75 (0.98-3.13)  1.54 (0.98-2.98) 
Isles 66 (11.7) 0.67 (0.49-0.91)*  0.66 (0.46-0.94) 
Northeast 52 (17.5) 1.07 (0.76-1.52)  0.92 (0.67-1.43) 
South 43 (9.9) 0.56 (0.39-0.80)**  0.53(0.36-0.79)** 
Geographic Area (grouped)    
Else 126 (11.8) 1[Reference]   
North 201 (16.8) 1.50 (1.18-1.90)**   
OR= Odds ratio; CI= confidence interval 95%;(g)=grouped data; *= P<0.05; **=P<0.01; ***P<0.001 
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Table 2 Univariable and multivariable analysis of the predictors of the use of phytotherapy 
(part II) 
 
  Univariable  Multivariable 
Characteristics Herbal use N (%) OR (95% CI)  OR (95%CI) 
Quantiles of years disease     
≤3 yrs 80 (14.0) 1[Reference]  1[Reference] 
4-7 yrs 95 (16.5) 1.22 (0.88-1.68)  1.24 (0.88-1.77) 
8-12 yrs 71 (14.3) 1.03 (0.73-1.45)  1.08 (0.74-1.58) 
>12 yrs 72 (14.8) 1.07 (0.76-1.51)  0.99 (0.67-1.48) 
  Univariable  Multivariable 
Characteristics Herbal use N (%) OR (95% CI)  OR (95%CI) 
Disease severity (symptoms, limitations in movements)   
None/minimal 186 (14.3) 1[Reference]   
Mild 56 (17.8) 1.30 (0.94-1.81)   
Moderate 37 (14.6) 1.03 (0.70-1.51)   
Support needed for walking 28 (15.5) 1.10 (0.71-1.70)   
Walker/two-handed crutch 6 (8.0) 0.52 (0.22-1.22)   
Unable to walk 8 (13.1) 0.91 (0.42-1.94)   
Disease severity (grouped)   
None/minimal or mild 242 (15.0) 1[Reference]   
Moderate/some support needed 65 (15.0) 1.00 (0.75-1.35)   
Severe (walker, c/unable to walk) 14 (10.3) 0.65 (0.37-1.15)   
Satisfaction for conventional treatment for MS   
A lot 118 (14.1) 1[Reference]   
Somehow 143 (14.3) 1.02 (0.78-1.33)   
Little  28 (15.7) 1.14 (0.73-1.79)   
No  8 (15.7) 1.14 (0.52-2.48)   
No answer 30 (15.2) 1.09 (0.71-1.69)   
Satisfaction for conventional treatment for MS (g)   
A lot/somehow 261 (14.2) 1[Reference]   
Little/no 36 (15.8) 1.12 (0.77-1.65)   
No answer 30 (15.2) 1.08 (0.72-1.63)   
Satisfaction for conventional treatment of side effects   
A lot 34 (16.8) 1[Reference]  1[Reference] 
Somehow 68 (18.9) 1.15 (0.73-1.81)  1.05 (0.64-1.75) 
Little  15 (22.4) 1.42 (0.72-2.82)  1.12 (0.50-2.50) 
No  3 (16.7) 0.98 (0.27-3.60)  1.15 (0.26-5.12) 
No answer 207 (12.8) 0.72 (0.49-1.08)*  0.79 (0.51-1.23) 
OR= Odds ratio; CI= confidence interval 95%;(g)=grouped data; *= P<0.05; **=P<0.01; ***P<0.001 
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Table 2 Univariable and multivariable analysis of the predictors of the use of phytotherapy 
(part III) 
 
  Univariable  Multivariable 
Characteristics Herbal use N (%) OR (95% CI)  OR (95%CI) 
Satisfaction for conventional treatment of side effects (g)   
A lot/somehow 102 (18.2) 1[Reference]   
Little/no 18 (21.2) 1.21 (0.69-2.13)   
No answer 207 (12.8) 0.66 (0.51-0.86)*   
Satisfaction for conventional treatment of diseases other than MS   
A lot 42 (16.3) 1[Reference]  1[Reference] 
Somehow 134 (20.4) 1.31 (0.90-1.93)  1.50 (0.98-2.29) 
Little  24 (20.9) 1.36 (0.78-2.37)  1.60 (0.85-3.02) 
No  5 (38.5) 3.21 (1.0-10.31)*  4.54 (1.18-17.50)* 
Satisfaction for conventional treatment of diseases other than MS (g)   
A lot/somehow 176 (19.3) 1[Reference]   
Little/no 29 (22.7) 1.22 (0.79-1.92)   
No answer 122 (10.0) 0.46 (0.36-0.60)***   
Use of alternative medicine     
Yes 243 (24.2) 1[Reference]   
No  61 (8.2) 0.28 (0.21-0.37)***   
No answer 23 (4.5) 0.15 (0.09-0.23)***   
Perception of benefit from CAM use   
Yes 126 (31.7) 1[Reference]  1[Reference] 
Partially  95 (22.1) 0.61 (0.45-0.83)**  0.60 (0.43-0.83)** 
No  16 (16.0) 0.16 (0.23-0.73)**  0.43 (0.23-0.80)** 
No answer 90 (6.7) 0.16 (0.12-0.21)***  018 (0.13-0.25)*** 
 
OR= Odds ratio; CI= confidence interval 95%;(g)=grouped data; *= P<0.05; **=P<0.01; ***P<0.001 
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Table 3. Most popular (≥5 users) herbal products listed 
Herbs  N % Respondents % Users 
Propolis 40 8,1 4,6 
aloe vera 37 7,5 4,3 
Valerian 31 6,3 3,6 
Ribes nigrum 18 3,6 2,1 
“Infusion” (NS) 18 3,6 2,1 
Arnica 15 3,0 1,7 
Echinacea 14 2,8 1,6 
“10 erbe” 13 2,6 1,5 
Ginseng 11 2,2 1,3 
Blueberry 11 2,2 1,3 
Uva ursi  11 2,2 1,3 
Calendula 8 1,6 0,9 
Hypericum perforatum 7 1,4 0,8 
papaya   7 1,4 0,8 
Ginkgobiloba 6 1,2 0,7 
“Herbalife” 6 1,2 0,7 
“PC 28” 6 1,2 0,7 
Devil's claw 5 1,0 0,6 
Chamomile    5 1,0 0,6 
Liquorice 5 1,0 0,6 
“Sollievo” 5 1,0 0,6 
Laxative infusion 5 1,0 0,6 
Veravis 5 1,0 0,6 
“10 erbe”, “PC28”, “Sollievo” and “Veravis”: dietary supplements containing multiple herbal 
components; NS= not specified 
 
 
Table 4. Selection of herbs among the list of commonly used in literature 
Herbs  N % Respondents % Users 
Ginseng 282 50,1 32,7 
Hypericum perforatum 122 21,7 14,2 
Liquorice 113 20,1 13,1 
Echinacea 105 18,7 12,2 
Gingko Biloba 85 15,1 9,9 
Garlic 30 5,3 3,5 
Enotera 22 3,9 2,6 
Kawa kawa 8 1,4 0,9 
Arecha catechu 1 0,2 0,1 
Other 158 28,1 18,3 
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Table 5. Place of purchase of herbal remedies 
 N 
% 
Respondents 
% 
Users 
Herbalist’s shop 462 60,6 53,6 
Pharmacy 373 48,9 43,3 
Supermarket/drugstore 60 7,9 7,0 
Other  39 5,1 4,5 
Direct producer  12 1,6 1,4 
Home growing 5 0,7 0,6 
Friends  3 0,4 0,3 
Parapharmacy 3 0,4 0,3 
Physician 2 0,3 0,2 
At home 2 0,3 0,2 
Naturopath 2 0,3 0,3 
smart shop 1 0,1 0,1 
Whenerver it happens 1 0,1 0,1 
Bar 1 0,1 0,1 
WEB 1 0,1 0,1 
By mail 1 0,1 0,1 
Missing answer 8 1,0 0,9 
Missing answer 99  11,5 
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Conclusions 
Pharmacoutilization studies allow to obtain a picture of medication pattern as well as DS/HR 
and other substances such as doping agent use within a selected population.  
I have observed that polypharmacy was quite common in outpatients attending a dental clinic 
and an increasing risk of DDI with age and drug used. These findings underline the crucial 
importance of a preoperative assessment including a complete evaluation, documenting all the 
medications as well as DS and HR within the dental record.  
Medication profiles and potential DDI knowledge is essential for safe practice in dentistry and 
also represents an important base for planning undergraduate as well as postgraduate teaching 
in clinical pharmacology. 
The results from élite cyclers confirmed the widespread use of DS  despite the lack of 
evidence about their efficacy and the potential risks. Moreover, I have noticed a superficial 
and “hematic-oriented” doping together with a potential hidden use, suggested by “denial 
policy”.  
As a whole, I have observed a widespread interest in DS and AS by fitness centre visitors and, 
in particular, among bodybuilders, as well as a very limited and selective perception of related 
risks. 
The results of the present studies, therefore, provide the basis for direct interventions aimed at 
increasing the knowledge and awareness of the risks in doping in both élite and recreational 
sports through educational and preventive programs. These measures aimed at reducing the 
improper use of substances in recreational athletes appears to be of critical importance at the 
individual as well as at the societal level.  
Therefore, physician should not only be an active part in the promotion of sport and exercise, 
but also be aware of DS and other performing-enhancing drug use.  
Trainers, who represent one of the main advisors should acquire specific knowledge about the 
about actual effectiveness, safety and legality of DS use.  
In the survey among MS patients, HR use appeared to be quite common, with the attempt to 
follow a healthy lifestyle, together with dissatisfaction with conventional drug treatment. 
However, the tendency in our sample was not to give up conventional treatment in lieu of 
herbal remedies, but to use them as adjuvant. 
Features associated with HR use in our sample were represented by: female, with a higher 
level of education, living in the, being dissatisfied with the conventional treatment of diseases 
other than MS, using and being satisfied by complementary and alternative medicine . 
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The degree of involvement of the caring physician (source of information, disclosure) in 
herbal treatment appears to be scarce, with considerable risks of adverse drug reactions an 
potential interferences with drug therapies.  
In conclusion, pharmacoutilization survey represent a suitable tool to gather information 
about use, knowledge and attitudes towards drugs and other substances such as DS/HR, 
doping or other illicit agents. Collected data may help to find out potential predictors 
associated with the use of these substances and, therefore, to identify subjects who may 
benefit by an educational intervention. 
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Pharmacovigilance 
 
During my PhD study programme I have also followed other pharmacoepidemiologic topics 
dealing with pharmacovigilance a discipline focused on monitoring the safety profile in the 
real life setting. Indeed, pre-marketing clinical trials usually involve a relatively small and 
usually selected (age, sex, absence of other comorbidity, etc…) number of patients for a 
relatively short period of time. However, once marketed, drugs will not be used under the 
same conditions and may be used by millions of patients, across a wide range of age groups, 
who may also be affected by other comorbidity and may be taking other medications. Though 
clinical trials are usually able to detect the more common and predictable adverse drug 
reactions (ADR), rarer ADR may only be highlighted once the drug is used by a large number 
of patients under the conditions of everyday use. 
The case report represents the basilar and simplest approach to pharmacovigilance, however, 
it is not a suitable tool in case of rare (<1/100'000) ADR However, due to their low frequency 
and difficult differential diagnosis, they are hardly detected through spontaneous reporting 
systems. Case-control studies are suitable tools to identify such rare and often life-threatening 
ADR, however they require collaborative network able to afford adequate quantity/quality of 
data.  
Hereafter will follow the abstract list of case report/case series of unusual ADR presented at 
national and international meetings. The ADR has been evaluated by in the light of the 
available literature and according to OMS causality assessment criteria 
- Finasteride-Associated Central Serious Chorioretinopathy, 8th ISOP 
Annual Meeting, Buenos Aires, 2008; Drug Safety 2008; 31 (10): 885-960 
- Bisphosphonate-Related Osteonecrosis of the Jaw: Description of Six 
Cases, 9th ISOP Annual Meedting, Reims, 2009; Drug Saf 2009;32(10 
- Collaborative Hospital-Based Surveillance Network of Drug-Induced 
Pancreatitis: A Feasibility Study in Italy, 8th ISOP Annual Meeting, Buenos 
Aires, 2008, 34° Congresso Nazionale SIF, Rimini, 2009, Drug Safety 2008; 31 (10): 885-
960. This study was realized by a grant of Ministry of Health for pharmacovigilance 
activities (DGR VII/8501 del 22.03.02)  
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- Hepatotoxicity after high-dose methylprednisolone for demyelinating 
disease.  
This case report has been presented at 7th ISOP Annual Meeting, Bornemouthm, UK, 2007 
and published in extenso in Clin Neuropharmacol. 2010 Jan-Feb;33(1):52-4. 
 
Abstract 
Liver toxicity, although not mentioned among the possible adverse effects of corticosteroids, 
has been occasionally reported in literature. We observed 2 cases of hepatotoxicity after a 
high-dose methylprednisolone treatment of a demyelinating disease and evaluated the 
potential relationship in the light of available evidence. The first patient developed a 
histologically documented acute hepatitis and recovered after 3 weeks. In the second patient, a 
mild augmentation of liver enzymes occurred, followed by normalization in a few days. The 
causal relationship between hepatotoxicity and methylprednisolone treatment was deemed 
probable in both cases. Careful review of the literature suggests that corticosteroid-induced 
liver damage may be more frequent than commonly believed. 
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